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Abstract
Despite enormous efforts to combat malaria, the disease still afflicts up to half a billion
people each year, of which more than one million die. Currently no effective vaccine is
within sight, and resistances to antimalarial drugs are wide-spread. Thus, new medicines
against malaria are urgently needed.
In order to aid the process of drug target detection, the present work carries out
a computational analysis of the metabolism of Plasmodium falciparum, the deadliest
malaria pathogen. A comprehensive compartmentalized metabolic network is assem-
bled, which is able to reproduce metabolic processes known from the literature to occur
in the parasite. On the basis of this network metabolic fluxes are predicted for the
individual life cycle stages of P. falciparum. In this context, a flux balance approach is
developed to obtain metabolic flux distributions that are consistent with gene expres-
sion profiles observed during the respective stages. The predictions are found to be in
good accordance with experimentally determined metabolite exchanges between para-
site and infected erythrocyte. Knockout simulations, which are conducted with a similar
approach, reveal indispensable metabolic reactions within the parasite. These putative
drug targets cover almost 90% of a set of experimentally confirmed essential enzymes
if the assumption is made that nutrient uptake from the host cell is limited. A com-
parison demonstrates that the applied flux balance approach yields target predictions
with higher specificity than the topology based choke-point analysis. The previously
predicted stage-specific flux distributions allow to filter the obtained set of drug target
candidates with respect to malaria prophylaxis, therapy or both, providing a promising
starting point for further drug development.
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Zusammenfassung
Trotz weltweiter Bemühungen, die Tropenkrankheit Malaria zurückzudrängen, erkran-
ken jährlich bis zu einer halben Milliarde Menschen an Malaria mit der Folge von über
einer Million Todesopfern. Da zur Zeit eine wirksame Impfung nicht in Sicht ist und
sich Resistenzen gegen gängige Medikamente ausbreiten, werden dringend neue Anti-
malariamittel benötigt.
Um die Suche nach neuen Angriffsorten für Medikamente zu unterstützen, unter-
sucht die vorliegende Arbeit mit einem rechnergestützten Ansatz den Stoffwechsel von
Plasmodium falciparum, dem tödlichsten Malaria-Erreger. Basierend auf einem aus dem
aktuellen Forschungsstand rekonstruierten metabolischen Netzwerk des Parasiten wer-
den metabolische Flüsse für die einzelnen Stadien des Lebenszyklus von P. falciparum
berechnet. Dabei wird ein im Rahmen dieser Arbeit entwickelter Fluss-Bilanz-Analyse-
Ansatz verwendet, der ausgehend von in den jeweiligen Entwicklungsstadien gemessenen
Genexpressionsprofilen entsprechende Flussverteilungen ableitet. Für das so ermittelte
stadienspezifische Flussgeschehen ergibt sich eine gute Übereinstimmung mit bekannten
Austauschprozessen von Stoffen zwischen Parasit und infiziertem Erythrozyt. Knockout
Simulationen, die mit Hilfe einer ähnlichen Vorhersagemethode durchgeführte werden,
decken essentielle metabolische Reaktionen im Netzwerk auf. Fast 90% eines Sets von
experimentell bestimmten essentiellen Enzymen wird wiedergefunden, wenn die Annah-
me getroffen wird, dass Nährstoffe nur begrenzt aus der Wirtszelle aufgenommen werden
können. Die als essentiell vorhergesagten Enzyme stellen mögliche Angriffsorte für Me-
dikamente dar. Anhand der Flussverteilungen, die für die einzelnen Entwicklungsstadien
berechnet wurden, können diese potenziellen Targets nach Relevanz für Malaria Pro-
phylaxe und Therapie sortiert werden, je nachdem, in welchem Stadium die Enzyme
als aktiv vorhergesagt wurden. Dies bietet einen vielversprechenden Startpunkt für die
Entwicklung von neuen Antimalariamitteln.
Schlagwörter:
Malaria, Metabolisches Netzwerk, Wirkstoff Angriffsort, Fluss-Bilanz-Analyse
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Chapter 1
Introduction
Malaria represents one of the major health issues worldwide. According to estimations of
the World Health Organization (WHO), there were around 250 million clinical cases and
almost one million disease related deaths in 2006, of which more than half were children
under the age of five [545]. About 50% of the world population lives in endemic areas,
situated mostly in Africa, Asia, and South-America (see Fig. 1.1). Especially in Africa,
where about 90% of the malaria cases occur, the disease has significant negative impact on
the economic development [428].
Figure 1.1: Malaria endemic countries. Estimated incidences of malaria in 2006 per 1,000
population (source: [545]).
The disease, which is characterized by periodical fever attacks, is caused by protozoan
parasites of the genus Plasmodium. Among the five Plasmodium species that are able to
infect humans, P. falciparum is responsible for 90% of the disease related deaths. Pathogens
are typically transfered by tropical mosquitoes to the human host where they first multiply
within the liver and subsequently periodically within erythrocytes.
Malaria exists presumably for more than 50,000 years [232]. It was once widespread, not
only in today’s endemic areas, but also in most of Europe and North-America. A worldwide
program to eradicate malaria with the aid of the insecticide DDT (dichlorodiphenyltrichloro-
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ethane) and available antimalarials was initiated in the 1950s by the WHO. The extinction
of the disease was successful in Europe, North-America, the Soviet Union and Australia,
but not in underdeveloped countries in tropical areas. Nowadays, only about one thousand
malaria cases occur in Germany every year, of which all are imported from other countries.
Experts see only little chances for the return of malaria to Germany, since a good health care
system exists and a critical amount of infected people is missing. However, mosquito species
able to transmit the disease exist in Germany and due to global warming temperatures that
are needed for pathogen development might not be uncommon in the future [578].
Several non-profit initiatives, including the WHO and its Roll Back Malaria partnership,
the Bill and Melinda Gates Foundation, the Global Fund to Fight AIDS, Tuberculosis and
Malaria as well as the Affordable Medicines Facility for Malaria, have recently reintroduced
the agenda of complete eradication of malaria in all countries [416]. In order to achieve this
goal of extinction of all Plasmodium species causing malaria in humans, effective drugs and
vaccines are needed to treat and prevent malaria.
The malaria parasite is able to outwit the host’s immune system by hiding within host
cells and avoiding clearance through the spleen with the help of highly variable proteins
that are transported to the surface of infected erythrocytes, allowing adherence to walls
of blood vessels. Therefore, vaccine development is challenging with the result that up to
now no approved vaccine is available to facilitate long-term malaria prophylaxis. The global
initiative Malaria Vaccine Technology Roadmap seeks to develop a malaria vaccine by 2025
that has a protective efficacy of more than 80% and lasts longer than four years [213].
Currently used antimalarial drugs correspond to five major drug classes (quinolines, an-
tifolates, artemisinin derivatives, antibiotica and the ubiquinone analog atovaquone). Due
to the strong selection pressure associated with the administration of antimalarials, drug
resistances have been developed in many areas [190, 14]. Recently, reduced susceptibility
even to artemisinin-based combination therapies, the recommended first-line treatments of
falciparum malaria, has been reported in western Cambodia [122]. Mechanisms of resis-
tance are still uncertain for most of the currently used drugs, making the process of drug
development even more complicated.
As resistances to currently used antimalarials are spreading and a vaccine providing full
and long lasting protection against clinical disease is not expected to be available soon,
new effective antimalarial drugs are needed. This demand has been neglected in the last
years by the pharmaceutical industry, due to the limited buying power of the population of
disease-endemic countries, making cost coverage of research and development investments
uncertain. To overcome this shortage in discovery of novel antimalarials, which can be sold
at affordable prices, non-profit collaborations have been established between academia and
pharmaceutical industry such as the Medicines for Malaria Venture [358].
A very crucial step in drug discovery is the identification of appropriate biological drug
targets, as improper target selection has been found to be the main cause for the high
failure rate of drug development [71]. Most of the currently used antimalarial drugs act on
enzymes and thus interfere with the metabolism of the parasite [560, 220, 91]. This trend
has also been found for marketed small-molecule drug targets in man of which almost 50%
are enzymes [208]. Therefore, investigating the metabolic network of the malaria pathogen
seems to be a promising approach to identify novel drug targets.
The majority of antimalarials interferes with the asexual blood stages of the parasite
and are thus suitable for treatment of disease symptoms. In order to successfully eradicate
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malaria more drugs will be needed which additionally hamper transmission of parasites by
mosquitoes and kill liver stages to prevent the onset of the disease. Thorough analysis of the
pathogen’s individual life cycle stages will therefore be a prerequisite for the development
of such drugs.
Advances in high-throughput technologies such as high-throughput genome sequencing,
microarrays, mass-spectrometry, yeast two-hybrid assays and chromatin immunoprecipita-
tion (ChIP)-chip assays have facilitated organism specific large-scale
“omics” studies. It is now possible to analyze cells on a genome wide scale with respect to
genomic sequences (genomics), gene expression levels (transcriptomics), expressed proteins
and posttranscriptional protein modifications (proteomics), the set of present small-molecule
metabolites (metabolomics) and physical interactions between proteins or proteins and DNA
(interactomics). In order to evaluate this wealth of available large-scale data the young re-
search field systems biology has evolved which has the goal to understand the complex and
dynamic processes within a cell. In contrast to classical molecular biology, not only the
separate system components are considered, but also the interactions between them. Based
on experimental data, mathematical models describing the biological system are developed.
Computers can therefore be used to simulate the behavior of the system of interest and to
predict effects of system perturbations, e.g., the consequences of administering a drug that
inhibits a certain enzyme. In an iterative process, model derived predictions are evaluated
with wet lab experiments, and in case experiments and prediction disagree, the model is
refined to further improve prediction quality (see Fig. 1.2). A systems biology approach
has the advantage that system wide effects of local changes can be estimated, thus revealing
how to control or optimize parts of the system. This is beneficial especially for medical ap-
plications where drug targets are sought whose inhibition have large effects on the system,
as well as for biotechnological applications where the yield of certain processes has to be
optimized.
Comprehensive biochemical networks, including metabolic networks [360], transcriptional
regulatory networks [198, 193] and signaling networks [376], have been reconstructed and
transformed into mathematical models on the basis of experimental high-throughput data.
Especially metabolic networks have become available for multiple organisms from all three
major domains of the tree of life [12, 84, 125, 298, 174, 138, 359, 139, 218, 443]. These
reconstructions have been the subject of different applications like metabolic engineering,
drug target discovery and network property analysis (see review [360] for more details). In
general, good accordance between predictions and experimental data could be observed in
these studies. For example, gene knockout simulations in yeast showed that predictions
with 95% sensitivity and 86% specificity are possible [478], suggesting that systems biology
approaches represent a valuable strategy.
Multiple studies using high-throughput technologies have been conducted to examine
malaria pathogens. Genome sequences of the species P. falciparum, P.vivax and P.knowlesi
are now available [161, 75, 370] and allow comparative analysis of these organisms. Fur-
thermore, the presence of gene transcripts and proteins has been evaluated for several de-
velopmental stages of the parasites [59, 419, 427, 501, 147, 275, 276, 185, 112, 501]. Lately,
even metabolite levels have been measured during different time points of the blood stage
[503, 366]. Several groups have started to reconstruct the metabolic network of P. falci-
parum [170, 561, 241, 309], and the network topology has been analyzed with respect to
putative drug targets [561, 136]. However, a consistent compartmentalized computational
3
Chapter 1 Introduction
Hypothesis
Data
Model Experiment
Systems
Biology
Simulation Validation
AnalysisConstruct/refinemodel
Figure 1.2: Iterative cycle of systems biology. Systems biology aims at understanding complex
biological systems by combining experiments and computational modeling. In an iterative cycle
a model of the system of interest is constructed and refined based on experimental data, while
experiments are designed to investigate hypotheses suggested by simulations. By this means
a model is developed that is eventually able to correctly predict the behavior of the system,
thus increasing biological knowledge.
model that can be used to make life cycle stage-specific predictions does not exist yet. Such
a model could contribute to elucidate the metabolism of malaria pathogens during the dif-
ferent life cycle stages and hence help to identify suitable drug targets, expediting the drug
discovery process.
1.1 Objectives of this work
The goal of the present work is to study the metabolism of Plasmodium falciparum, the dead-
liest human malaria pathogen, with the help of systems biology methods, thus contributing
to the fight against malaria. In this context, the first multi-compartment metabolic network
of P. falciparum is assembled, which comprises data from publicly available sources. On the
basis of this comprehensive network, metabolic flux distributions consistent with observed
gene expression profiles are predicted, using a flux balance approach. By this means, meta-
bolic fluxes can be inferred for all life cycle stages of the parasite for which gene expression
levels have been measured. As especially the liver stage of P. falciparum is difficult to study
and experimentally determined flux rates will not be available soon on genome scale for any
life cycle stage, this computational approach is intended to augment available experimental
data. In addition, the metabolic network of P. falciparum is analyzed with respect to es-
sential enzymes which presumably represent good drug targets. Among these drug target
4
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candidates those suitable for malaria prophylaxis or treatment can be determined with the
help of predicted life cycle stage-specific metabolic fluxes, as such enzymes have to be active
during the liver stage or the blood stage, respectively. Additional criteria like homology to
human enzymes and functional similarity to therapeutic targets in other organisms help to
further filter the set of putative targets.
1.2 Outline of the working program
In the following, an introduction to the topic malaria is given (Chapter 2), explaining the
life cycle of the pathogen as well as disease symptoms and ways to diagnose and treat
the disease. Furthermore, known antimalarial drug targets are summarized and the process
underlying the discovery of new drugs is described. Chapter 3 reviews available experimental
large scale data for P. falciparum, in particular gene expression data, which can be used
to model the metabolism of the parasite. Databases relevant for the modeling process
and related computational approaches are outlined in Chapter 4. This chapter includes
methods allowing the prediction of metabolic fluxes on the basis of gene expression data
and proposed approaches to identify putative drug targets in metabolic networks. The
assembly of the compartmentalized metabolic network of P. falciparum as well as the human
erythrocyte, one of the parasite’s host cells, is described in Chapter 5. Subsequently, the
approach applied to these networks in order to infer life cycle stage-specific metabolism
is explained and predicted flux distributions are evaluated with respect to experimentally
observed metabolite exchanges between host and parasite and in addition with proteomics
and metabolomics data (Chapter 6). Finally, putative drug targets in the metabolism of P.
falciparum detected by an in silico knockout study are evaluated and ranked (Chapter 7).
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Biological background
2.1 The disease malaria
2.1.1 The pathogen
Originally, people thought that malaria (ital.: mala aria = bad air) is caused by the air
coming from swamps due to disease occurrence in these areas. Only since the discovery
by Charles Louis Alphonse Laveran in 1880 of moving crescent-shaped bodies in a blood
drop from a sick soldier it is known that protozoan parasites of the genus Plasmodium cause
the disease [277]. Five species are pathogenic to humans: Plasmodium falciparum, which
is responsible for 90% of the disease related deaths, Plasmodium vivax, Plasmodium ovale,
Plasmodium malariae as well as the primate malaria parasite Plasmodium knowlesi.
Plasmodium parasites are unicellular eukaryotes that not only use humans as hosts, but
also rodents, birds, monkeys and reptiles. Beside a nucleus the parasites possess a mitochon-
drion [517], a chloroplast-like organelle without photosynthetic activity called apicoplast
[403], an endoplasmic reticulum (ER) [516] and a golgi apparatus [487]. In addition, a food
vacuole [120] and secretory organelles (rhoptries, micronemes and dense granules) [245] de-
velop during certain time points of the parasite’s life cycle, contributing to the different
morphological states. The genome of P. falciparum consists of 14 nuclear chromosomes and
has a size of ∼ 23 Mb. In addition, a small linear genome exists in the mitochondrion (∼ 6
kb) and a small circular genome in the apicoplast (∼ 35 kb). A first draft of the genome
sequence was published in 2002 [161], revealing an unusually high percentage of A/T con-
tent (80.6%). Bioinformatics approaches identified more than 5,300 open reading frames, of
which up to now only half are functionally annotated.
2.1.2 The life cycle of Plasmodium falciparum
P. falciparum has a rather complex life cycle, since it involves different hosts and tissues
[510] as depicted in Fig. 2.1. Typically, a cycle starts with an infected female anopheline
mosquito taking a blood-meal and thereby injecting parasites into the human blood stream.
These sporozoites travel then to the liver where they invade hepatocytes and undergo asex-
ual replication known as exo-erythrocytic schizogony, which involves multiple rounds of
nuclear division without cytokinesis. In contrast to P. falciparum, Plasmodium vivax and
Plasmodium ovale may rest within hepatocytes (hypnozoite stage) before they proceed with
development months or even years later. The progeny of one parasite can consist of several
thousand new parasites. These so-called merozoites leave the liver in hepatocyte-derived
vesicles (merosomes) that protect the parasites from the host immune system. Merozoites
6
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Figure 2.1: Life cycle of P. falciparum. The different parasite forms during the life cycle are
annotated to the respective stages. Graphics are modified from [150, 362, 99].
released into the circulation are able to infect erythrocytes which serve the parasites as an-
other nutrient resource. The intraerythrocytic developmental cycle (IDC) comprises several
stages. Due to its characteristic morphology, the early stage is referred to as the ring form
which is followed by the trophozoite stage and the formation of schizonts. The release of up
to 32 new merozoites after asexual reproduction in erythrocytes triggers the symptoms of
malaria, since parasite specific particles are set free that activate the human immune system.
In some cases parasites differentiate during the blood stage into female (macrogametocytes)
and male (microgametocytes) gametocytes, which have no further activity within the human
host. If a mosquito takes a blood meal, gametocytes get into the midgut of the mosquito
where the environmental conditions induce the fertilization of macrogametes by microga-
metes. The resultant ookinete builds a cyst on the outside of the stomach wall (oocyst),
producing sporozoites (sporogony) that travel to the salivary gland of the mosquito after
oocyst rupture. Here the sporozoites wait to be reinjected into the human blood stream to
start a new cycle.
2.1.3 Clinical symptoms
Malaria symptoms [177, 510] occur, depending on the the Plasmodium species, 7–15 days
(P. falciparum), 12–18 days (P. vivax, P. ovale) or 18–40 days (P. malariae) subsequent
to a mosquito bite. Longer periods of incubation are possible due to ineffective use of
prophylactic drugs or the formation of dormant liver forms (hypnozoites), leading to latency
periods up to 40 years. Disease symptoms include flu-like symptoms such as fever, headache,
shivering, joint pain and vomiting which makes it sometimes difficult to diagnose malaria.
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In addition anemia, hemoglobinuria, convulsions, splenomegaly, hepatomegaly through to
kidney failure, circulatory collapse and coma may occur. Malaria is characterized by a
cyclical onset of symptoms, every second day for P. vivax and P. ovale infections (malaria
tertiana) and every third day for P. malariae (malaria quartana). P. falciparum causes
either fever, recurring in periods shorter than two days, or less intensive continuous fever
(malaria tropica). Malaria episodes typically start with an intense feeling of cold and
vigorous shivering (cold stage), followed by fever with body temperatures of 40 ◦C (hot
stage). After three to four hours temperature declines to normal accompanied by strong
sweating (sweating stage). Symptoms are triggered by the rupture of infected erythrocytes
which release not only new parasites, but also toxins, inducing the secretion of cytokines by
cells of the immune system. Cytokines are responsible for the fever as well as a decreasing
blood sugar level and suppression of erythrocyte production in the bone marrow. Together
with parasite induced lysis of erythrocytes and removal of infected cells by the spleen this
may result in severe anemia. P. falciparum is the only human malaria pathogen that is
able to produce proteins which are exported to the erythrocyte cell surface and have the
ability to adhere to endothelial cells of blood vessels. As a consequence blood circulation
is impaired in affected tissues, causing a shortage of oxygen and nutrients. Malaria may
result in life-threatening coma (cerebral malaria) or severe adverse outcomes for pregnant
women and their babies (placental malaria) if the central nervous system is involved or the
placenta.
2.1.4 Clinical diagnostics
The most common technique to diagnose malaria are microscopic examinations of blood
films, either using thin films or thick films derived from a larger volume of blood [177, 510].
While analyses of thick films are more sensitive and are therefore used in routine diagnosis,
thin films allow species identification. In areas, where microscopic examinations are not
possible, immunological tests are applied that allow the detection of parasitic antigens within
minutes. However, these test are relatively expensive, are less sensitive than thick blood
films and are not always able to distinguish the different Plasmodium species. The most
sensitive method to malaria is polymerase chain reaction (PCR), which detects parasitic
nucleic acids. But since PCR requires a specialized laboratory besides being expensive, it
is not often applied. In case none of the above mentioned diagnostic tests are available,
malaria may even be diagnosed upon symptoms such as periodic temperature patterns, nail
bed pallor and splenomegaly.
2.1.5 Treatment
Drugs currently used to treat malaria include five classes of compounds: quinolines (qui-
nine, chloroquine, amodiaquine, primaquine, mefloquine, piperaquine), antifolates (sulfa-
doxine, pyrimethamine, proguanil, chlorproguanil, dapsone), artemisinin derivatives (art-
emisinin, artesunate, artemether, OZ277), antibiotica (fosmidomycin, tetracyclines, clin-
damycin, azithromycin) and the ubiquinone analog atovaquone [332, 91]. The first widely
used antimalarial, quinine, was extracted in 1820 from the bark of the Andean Cinchona tree
which had been used in Peru to cure malaria and then brought to Europe by Jesuits. Later,
it was replaced by the more effective synthetic quinoline compound chloroquine which be-
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came the medication of choice due to its low production costs and few side effects. However,
in the last years resistances to this drug have emerged in many areas of the world [14]. The
antifolate fansidar, which consists of the active compounds sulfadoxine and pyrimethamine,
became an alternative drug to chloroquine until recently it started to fail as well [14]. The
world health organization currently advises to treat malaria on the basis of combination
therapies, meaning the simultaneous use of two or more drugs with unrelated targets in the
parasite to avoid fast progression of resistance development [368]. Artemisinin-based combi-
nation therapy (ACT) are recommended as first-line treatment for uncomplicated malaria in
areas experiencing resistance to older medications. Artemisinin is obtained from the plant
Artemisia annua, which has been used in traditional Chinese medicine for more than 2,000
years. In areas where resistances have not occurred yet, non-artemisinin based combinations
(non-ACTs), including fansidar with chloroquine or amodiaquine are advised.
2.1.6 Prevention
Efforts to prevent the spread of malaria include the control of mosquitos, the protection
of people from mosquito bites and the usage of prophylactic drugs. In order to reduce
mosquito populations, their habitats have been eliminated by draining and poisoning of
wetlands. Attempts of direct mosquito eradication have been made as well. In the 1950s
the insecticide DDT was applied in a worldwide campaign, which resulted in the elimination
of malaria among others in North-America and Europe. The discovery that DDT has
negative effects on the environment, especially on birds, and that mosquitos had developed
resistances discredited DDT. Today, insecticides are still used on the interior walls of homes
(Indoor residual spraying), where mosquitos were found to rest after a blood meal. Less
common strategies in mosquito control are radiation and genetic modification of mosquitos
to obtain species that are either steril and do not produce offspring upon mating or are
resistant to malaria and therefore do not transmit the disease anymore. Prevention of
disease transmission is the goal of bed nets which have been shown to provide protection
from mosquito bites, with improving results when treated with insecticides. This approach
takes advantage of the fact that Anopheles mosquitos feed at night.
Another branch of malaria prevention is chemoprophylaxis which aims at stopping the
disease before the onset of symptoms. Travelers in endemic areas have the option to take
prophylactic drugs such as mefloquine (Lariam), doxycycline and the combination of ato-
vaquone and proguanil hydrochloride (Malarone). Due to high costs and drug side effects,
this is not applicable for residents of malarial regions.
Natural immunity to malaria pathogens does only occur after repeated infection with
multiple Plasmodium strains. The acquired immunity, often referred to as malarial toler-
ance, is however not a sterile protection, but keeps parasitemia densities low and people are
free of symptoms for most of the time (clinical immunity). Up to now, there are no clini-
cally approved malaria vaccines available. Multiple vaccine candidates are currently under
development and testing, though [507]. Most candidates are based on the circumsporozoite
protein (CSP) which is present on the surface of sporozoites and was found to be bound
by antibodies of the immune system, preventing the sporozoite from invading hepatocytes.
The most promising candidate, a CSP derived vaccine, is RTS,S/AS02A, which will soon
enter Phase III clinical trials [64].
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2.1.7 Malaria drug targets
Most of the currently used antimalarials either target the metabolism of the pathogen or
the detoxification of heme which is produced during hemoglobin degradation of the blood
stage. In addition, most drugs are effective during the blood stage, the stage where malaria
symptoms occur. Due to the rapidly growing resistances to currently used drugs, new
antimalarials are urgently needed. New drugs can be developed either by designing new
molecules inhibiting established targets or by identifying novel putative targets. Table
2.1 reviews both known targets and putative novel targets for the rational design of new
antimalarial drugs [560, 220, 91].
Table 2.1: Established and suggested targets for antimalarial drugs.
Pathway Protein EC no. Ref.
Energy
metabolism
aldolase 4.1.2.13 [541, 223]
hexose transporter [229, 434]
lactate dehydrogenase 1.1.1.27 [509, 74]
Mitochondrial
electron
transport
NADH dehydrogenase 1.6.5.3 [267]
succinate dehydrogenase 1.3.99.1 [492]
cytochrome c reductase 1.10.2.2 [144]
Folate
metabolism
dihydrofolate reductase 1.5.1.3 [347, 142, 113]
dihydropteroate synthase 2.5.1.15 [347, 508, 316]
Heme
biosynthesis
δ-aminolevulinate synthase 2.3.1.37 [520, 493]
δ-aminolevulinate dehydratase 4.2.1.24 [55]
Protein
biosynthesis
ribosomes [546]
threonine-tRNA ligase 6.1.1.3 [425]
alanine-tRNA ligase 6.1.1.7 [102]
Protein
modification
peptide deformylase 3.5.1.88 [60]
protein-S-isoprenylcysteine-O-
methyltransferase
2.1.1.100 [34, 548]
farnesyl-diphosphate farnesyl-
transferase
2.5.1.58 [80]
protein farnesyltransferase [80, 547]
GPI
biosynthesis
N-acetyl glucosaminylphos-
phatidylinositol deacetylase
3.5.1.89 [477]
Isoprenoid
biosynthesis
1-deoxy-D-xylulose-5-phosphate
reductoisomerase
1.1.1.267 [230]
2-C-methyl-D-erythritol-2,4-
cyclodiphosphate synthase
4.6.1.12 [109]
Ubiquinone
biosynthesis
3-Demethylubiquinone-9,3-O-
methyltransferase
2.1.1.64 [308]
Polyamine
metabolism
ornithine decarboxylase 4.1.1.17 [20, 50, 42]
S-adenosylmethionine decarboxy-
lase
4.1.1.50 [556]
Continued on next page
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Table 2.1 – continued from previous page
Pathway Protein EC no. Ref.
spermidine synthase 2.5.1.16 [183]
Methionine
metabolism
adenosylhomocysteinase 3.3.1.1 [66, 468, 253,
326]
Phosphatidyl-
choline
synthesis
choline kinase 2.7.1.32 [92]
choline carrier [47]
phosphoethanolamine methyl-
transferase
2.1.1.103 [385, 553]
Type II fatty
acid
biosynthesis
3-oxoacyl-ACP synthase 2.3.1.41 [536, 396]
3-hydroxyacyl-ACP dehydratase 4.2.1.- [458]
acetyl-CoA-carboxylase 6.4.1.2 [536]
enoyl-ACP-reductase 1.3.1.9 [191, 494, 481]
Sphingolipid
metabolism
serine-palmitoyl transferase 2.3.1.50 [166]
sphingosine-N-acyltransferase 2.3.1.24 [166]
ceramide-cholinephospho-
transferase
2.7.8.3 [166]
ceramide-glycosyltransferase 2.4.1.80 [166]
Lipases phospholipase B 3.1.1.5 [577]
phospholipase C 3.1.4.3
sphingomyelinase 3.1.4.12 [384, 186]
surface phospholipase [46]
Purine salvage adenosine deaminase 3.5.4.4 [511, 165]
GMP synthetase 6.3.5.2 [314]
hypoxanthine guanine phosphori-
bosyltransferase
2.4.2.8 [115, 438, 285]
IMP dehydrogenase 1.1.1.205 [543]
purine nucleos. phosphorylase 2.4.2.1 [248]
adenylosuccinate synthetase 6.3.4.4 [129]
Pyrimidine
metabolism
carbamoyl phosphate synthetase 6.3.5.5 [148]
carbonic anhydrase 4.2.1.1 [411]
dihydroorotase 3.5.2.3 [455]
dihydroorotate oxidase 1.3.3.1 [266, 318]
orotidine-5’-phosphate decarboxy-
lase
4.1.1.23 [451, 454, 268]
thymidylate synthase 2.1.1.45 [225, 354]
ribonucleotide reductase 1.17.4.1 [33, 296, 79]
Shikimate
biosynthesis
5-enolpyruvyl-shikimate-3-
phosphate synthase
2.5.1.19 [415]
amino-deoxychorism. synthase 6.3.5.8 [169]
chorismate synthase 4.2.3.5 [318]
DNA
transcription
and replication
histone deacetylase [303]
topoisomerase I 5.99.1.2 [53]
topoisomerase II 5.99.1.3 [356, 159, 85]
Continued on next page
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telomerase [484, 7]
Hemoglobin
digestion
dipeptidyl aminopeptidase 1 3.4.14.1 [258]
falcipains (cysteine proteases) [469, 24, 423]
plasmepsins (aspartic acid pro-
teases)
3.4.23.38/
3.4.23.39
[357, 422]
histo-aspartic protease [30]
leucine aminopeptidase 3.4.11.1 [352]
M1-family aminopeptidase [146]
Heme detox. [490, 407]
Antioxidant
defense
γ-glutamylcysteine synthetase 6.3.2.2 [390, 295, 323]
glutathione reductase 1.8.1.7 [48, 574]
glyoxalase I 4.4.1.5 [505]
superoxide dismutase 1.15.1.1 [480]
thioredoxin reductase 1.8.1.9 [264, 295]
glutathione transferase 2.5.1.18 [187, 288, 383]
Prot. kinases cyclin-dep. protein kinases [259, 542]
Miscellaneous SERA4-6 [331]
sarco/ER Ca2+ ATPase [173]
subtilisin 1,2 [552, 512]
2.2 Drug discovery pipeline
In the past the discovery of drugs was often promoted by serendipity as it has been the
case for the discovery of penicillin by Alexander Fleming. Nowadays, with the availability
of many sequenced genomes, high-throughput technologies, combinatorial chemistry and
sophisticated bioinformatics methods, new drugs are filtered in a drug discovery pipeline
(see Fig. 2.2) from a large set of substances. The development of a market-ready drug
is a long (10-15 years) and expensive (∼$800 million per approved drug) process, thus
pharmaceutical companies try to eliminate unsuccessful substances as early as possible from
the pipeline. The first step of the pipeline is the assessment of available biological data for
the disease of interest and the market potential of corresponding drugs. In this course
questions are addressed like the existence of an adequate animal model and whether there’s
a market for the drug to recover research and development expenses. Then the search for a
suitable drug target begins. Improper selection during this phase has been found to be the
main cause for the high failure rate of drug development [71]. 90% of current drug targets
are either enzymes, G-protein coupled receptors, ion channels or transporters [208] and thus
encoded by genes. The human genome as well as the genomes of human pathogens therefore
represent large resources for potential targets. Genes that are further considered should
meet at least two criteria: First, they need to be involved in the disease, and second, they
should be druggable, meaning that their activities can be modulated through the binding
of therapeutic molecules. Genes fulfilling the first requirement can be identified with the
help of available information (literature searches, database mining) or conducted animal
studies and clinical trials. In addition, genome-scale transcriptome profiles, comparing gene
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Figure 2.2: Drug discovery pipeline.
expression levels of healthy and diseased tissue, suggest genes that are disease relevant.
Genes are assumed to fulfill the second requirement (druggability) if they belong to a gene
family with members known to be able to bind small molecules (development by analogy).
In general, choosing a target that is easily accessable to drugs and for which the protein
structure has been resolved or predicted, simplifies subsequent steps of the drug discovery
pipeline. For example, drug binding sites can be identified with bioinformatics methods if
structures of the targets are available.
In case the drug target is within a pathogen, the target has to be essential for the pathogen,
at least during its developmental stage in the human host. Computational analyses of
respective cellular networks (metabolic or signal transduction) can give hints on such targets
by unveiling those candidates that can not be circumvented by alternative paths (see section
4.4). In addition, genes homologous to the target should either be absent in the host or
sufficiently distinct to avoid unwanted side effects upon drug administration. Such genes
can be identified by comparative analyses of host and pathogen genomes.
Before a target can proceed in the drug discovery pipeline the importance of its role with
respect to the disease needs to be validated. This can be done either with chemical or
genetic methods [474], which complement each other. Chemical validation is accomplished
if there is experimental evidence for disease attenuation by specific inhibition of the target
with a chemical compound. This approach allows on the one hand to assess the likelihood
of successful drug delivery to the target, but on the other hand positive results can not
be unambiguously ascribed to the target, since the compound might bind unspecifically.
Genetic approaches such as gene deletion by homologous recombination or RNA interference
are thought to be more definitive with respect to testing the essentiality of a target for a
disease. However, if it is not possible to obtain null-mutants this does not necessarily mean
that the target is essential, since it needs to be tested in the appropriate life-cycle stage
and environment. Further evidence can be obtained from conditional knockouts that are
inducible during the stage of interest.
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When the target is settled a lead molecule that binds to the target is sought. High-
throughput screening (HTS) approaches that rely on miniaturized and automated assays
allow to test large libraries of compounds within a short time. If the 3D structure of a target
protein is known, the binding affinity of small molecules can alternatively be predicted by
computer-aided virtual screening approaches, or a compound that fits into the binding
pocket can be designed de novo. Those compounds (leads) that show high affinity for the
target are further optimized to increase selectivity and reduce toxicity. In this context, a
set of molecules that is structurally related to the lead compound is generated by means of
combinatorial chemistry and subsequently tested.
After the lead optimization process is finished, pharmacokinetics and pharmacodynamics
are tested in preclinical trials with animals. If these trials are successful the drug candidate
is tested with a small number of healthy humans (clinical phase I). In clinical phase II the
drug is administered to up to 500 hundred patients suffering from the respective disease
and in clinical phase III to more than 1,000 patients. If the drug is then approved by
the authorities of a country, commercialization of the drug may start and finally amortize
research and development costs.
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Available experimental data for P. falciparum
The modeling process of cellular systems is always accompanied by experimental data such
as kinetic constants which build a foundation for the computational model. With the advent
of high-throughput techniques several types of experimental data have become available on
genome-scale such as transcriptomic [59, 419, 427, 112, 501], proteomic [147, 185, 501] and
protein interaction data [273]. Compared to proteomics and metabolomics data [503] more
data is on-hand from measurements of gene transcript levels, providing a broad basis for
computational simulations.
3.1 Genome-wide transcriptomic data
Microarrays facilitate the analysis of the transcriptome and genomic characteristics of cells
in a high-throughput manner. Corresponding experiments basically consist of three steps.
In the first step, the array is designed and produced. Then data are collected during the
actual experiment which includes tissue preparation, mRNA isolation, mRNA labeling,
hybridization and scanning. Finally, scanner images are analyzed, data points normalized
and further evaluated in order to extract the underlying information. Different types of
microarrays are available that vary with respect to the following aspects of the production
process and application:
• array probes: cDNA (complementary DNA; obtained from mRNA by RT-PCR) vs.
oligo (synthesized short DNA fragments)
• probe fixation: spotting (spotting robot immobilizes probes on array) vs. in-situ
probe synthesis (probes are synthesized on array)
• one color (absolute experiment: only one sample per array) vs. two color exper-
iment (comparative experiment: two samples labeled with different fluorophores are
hybridized on same array)
In the last years several genome-scale experiments have been conducted, giving an insight
on the transcriptome of malaria pathogens during different life cycle stages.
3.1.1 Bozdech data set
One of the first genome-scale transcriptome studies of P. falciparum was published by
Bozdech et al. in 2003 [59]. Custom designed DNA microarrays with oligonucleotides
respresenting predicted open reading frames (ORFs) were used to monitor gene expression
during the intraerythrocytic developmental cycle (IDC) on an one hour timescale resolution.
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The individual mRNA samples were hybridized in a comparative experiment against a
reference pool comprising all extracted samples. The study revealed that the majority of
genes was expressed during the IDC, leaving only a small percentage of genes specific to
other developmental stages. Furthermore, about three quarters of those genes that were
transcribed during the IDC were found to be activated only once during the 48 hours cycle.
Evaluation of functionally annotated genes showed that the presence of gene transcripts
correlates well with the biological function of the respective proteins.
3.1.2 Le Roch data set
An approach for gene function annotation with the help of expression profiling [419] was
presented by Le Roch and colleagues. In this context they measured gene expression in P.
falciparum during the mosquito stage (salivary gland sporozoite), the sexual stage (game-
tocytes present in human blood) and seven time points of the erythrocytic asexual stage
(early and late ring stage, early and late trophozoite, early and late schizont, and merozoite).
Gene transcript levels were analyzed in an one-color approach with custom designed high-
density oligonucleotide arrays covering predicted coding and non-coding sequences. The
study demonstrated that genes with similar functions exhibit similar expression profiles and
thus microarray experiments can be used to further annotate functionally uncharacterized
genes.
3.1.3 Sacci data set
Gene expression during the liver stage of malaria pathogen development was analyzed on
genome-scale for the first time by Sacci et al. in 2005 [427]. Due to difficulties in these
analyses for the human parasite, they constructed a liver stage cDNA library for the rodent
parasite P. yoelii. Liver stage schizonts were extracted by laser capture microdissection.
Subsequently, mRNA was isolated, transcribed into cDNA and amplified. BLAST searches
with the sequenced cDNAs identified genes expressed during late liver stage.
3.1.4 Tarun data set
Recently, another transcriptome study for P. yoelii has been published by Tarun and col-
leagues [501], covering three time points during the liver stage (24 h, 40 h, and 50 h post-
infection) which they compared to two time points during the mosquito stage (10 days
(midgut) and 15 days (salivary gland) after blood meal) and two time points during the
blood stage (schizont and mixed blood stages). For efficient isolation of infected hepatocytes,
green fluorescent protein-tagged parasites and fluorescence activated cell sorting were uti-
lized. Parasitic liver stages were found to be highly metabolically active with up-regulated
mitochondrial activity.
3.1.5 Daily data set
Both above mentioned gene expression data sets covering the blood stage of P. falciparum
are obtained from blood cultures and thus might not fully reflect in vivo gene expression. In
contrast, the genome-scale transcriptome study presented by Daily and coworkers assesses
43 samples derived from the blood of P. falciparum infected patients which contain mostly
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ring stages of the parasite [112]. These samples were found to correspond to three groups:
starvation response accompanied by metabolism of alternative carbon sources (cluster 1),
active growth based on glycolytic metabolism (cluster 2) and environmental stress response
(cluster 3).
3.2 Further available high-throughput data
Most of the large-scale studies conducted for P. falciparum examined the transcriptome
of the parasite [59, 419, 112, 576] thanks to the relatively simple microarray technology
that allows to measure mRNA levels of thousands of genes simultaneously. Fewer time
points of the parasite’s life cycle have been analyzed with respect to present proteins. For
P. falciparum protein profiles of the blood stage [147, 275] as well as the mosquito stage
[147, 275, 276] have been determined. Up to now, the liver stage proteome has only been
analyzed for the rodent malaria pathogen P. yoelii. Mass spectrometry studies investigating
the proteome of the parasite recovered less protein species than were suggested to be present
by transcriptome analyses [501]. This might be due to varying levels of sensitivity inherent
to the detection methods.
Physical interactions between proteins have been assayed with a yeast two-hybrid system
that revealed almost 3,000 unique interactions. A lot less is known about the metabolome of
P. falciparum. About 50 metabolites have been identified by NMR spectroscopy in mature
trophozoites [503] and about 90 in a liquid chromatography-tandem mass spectrometry
study that analyzed seven time points of the intraerythrocytic developmental cycle [366].
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4.1 Relevant databases
4.1.1 Malaria Parasite Metabolic Pathways
A fundamental resource for information about the metabolism of Plasmodium falciparum is
the Malaria Parasite Metabolic Pathways (MPMP) website (http://sites.huji.ac.il/
malaria/) designed by H. Ginsburg [170], whose concern was to present available informa-
tion in a clear and educative way. The website is structured in more than 100 maps, not
only describing classical metabolic pathways and metabolite transport, but also biological
processes such as cell-cell interaction, replication, transcription and translation. Metabolic
pathway maps were manually derived from the KEGG database and adapted according
to the present knowledge of parasite biochemistry and annotations of the P. falciparum
genome. Pathways were considered to occur in P. falciparum if either most enzymes are
suggested by genome annotation or biochemical evidences imply their functionality. Thus,
certain enzymes may not be associated with any gene. Each enzyme entry is linked to sup-
plementary information from other databases, including PlasmoDB, GeneDB, BRENDA
and ExPASy ENZYME. In addition, enzymes are graphically annotated with information
on inhibitors as well as a 48h clock that displays gene transcription during the blood stage.
4.1.2 PlasmoCyc
PlasmoCyc (http://plasmocyc.stanford.edu/) is a metabolic pathway data-
base derived from the genome annotations of Plasmodium falciparum. A first draft of
PlasmoCyc was generated computationally with the PathoLogic software [372], which re-
quires a reference pathway database as input in addition to the genome annotation. Based
on annotated gene product qualifiers and EC numbers PathoLogic infers biochemical reac-
tions that occur within an organism. The more reactions of a pathway contained in the
reference pathway database are predicted, the more likely is the presence of the respective
pathway in the organism. The resulting network was complemented with pathways from
the Malaria Parasite Metabolic Pathways website as well as reactions extracted from sci-
entific literature. The online interface of the PlasmoCyc database visualizes the metabolic
network in the form of pathway maps. Enzymatic reactions are linked to more detailed
representations with chemical structures of involved metabolites as well as information on
the protein subunits of enzyme complexes. PlasmoCyc is integrated into the BioCyc website
which provides a collection of organism-specific pathway databases.
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4.1.3 KEGG
The Kyoto Encyclopedia of Genes and Genomes, or simply KEGG, is a knowledge base
developed and maintained by the Kanehisa lab in Kyoto (http://www.genome.jp/kegg/).
KEGG consists of four main databases (PATHWAY, BRITE, GENES and LIGAND) that
are divided into several subdatabases, containing data among others on enzymes, reactions,
diseases and drugs [239, 241, 240]. KEGG PATHWAY provides manually drawn pathway
maps, representing metabolic pathways and other cellular processes. On the basis of these
maps and the subdatabase KEGG orthology (KO), which catalogues orthologous genes,
organism specific metabolism can be inferred. Orthologous genes are determined in a semi-
automated procedure involving pairwise genome comparison and the integration of gene
clusters from the COG database [502] and protein families classified by experts. KEGG
provides tools to browse and search functional hierarchies, to analyze transcriptomic and
metabolome data in the context of pathway maps and to draw chemical compound structures
that can be used to search the KEGG databases.
4.1.4 BRENDA
BRENDA (BRaunschweig ENzyme DAtabase, http://www.brenda-enzy- mes.org) pro-
vides a comprehensive collection of biochemical and molecular information on more than
4,000 different metabolic enzymes classified according to the Enzyme Commission list of en-
zymes [82]. The manually curated database entries contain enzyme related information from
primary literature such as enzyme nomenclature, enzymeligand interactions, functional pa-
rameters, organism related information, information on enzyme structure, molecular proper-
ties and links to other databases. Two additional databases, AMENDA (Automatic Mining
of ENzyme DAta) and FRENDA (Full Reference ENzyme DAta), have been developed that
contain enzyme data extracted from PubMed abstracts by text-mining procedures. These
databases cover more organism-specific enzyme information than BRENDA, but are less
precise due to missing manual validation.
4.1.5 Reactome
The Reactome online platform http://www.reactome.org [524, 525, 309] represents a
comprehensive resource for human metabolic pathways all curated by expert biological re-
searchers and peer-reviewed. In addition, tools are provided for pathway visualization and
analysis of large-scale datasets such as transcription profiles. The curated human data is
used to infer pathways and reactions in non-human species with sequenced and annotated
genomes like Plasmodium falciparum. In this context similarity clusters are compiled on the
basis of reciprocal best similarity between human genes and those of an organism of inter-
est. If matching enzymes of a particular pathway are found in the organism, the pathway
is assumed to be present and missing enzymes are postulated.
4.1.6 Transport Classification Database
The Transporter Classification Database (TCDB) is a curated database cataloging mem-
brane transport proteins according to an IUBMB approved classification system [429, 430].
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Similar to the Enzyme Commission (EC) system for classification of enzymes, TCDB pro-
vides a classification of membrane transport proteins and in addition information about
protein sequence, structure and function as well as evolutionary information about trans-
port systems from multiple organisms including P. falciparum. The database is hosted at
http://www.tcdb.org/ and currently encompasses about 5,000 representative transporters
and putative transporters in more than 500 families which were compiled from primary lit-
erature. Several tools are offered that allow to classify newly identified membrane proteins
and to annotate genome sequences.
4.1.7 Gene Ontology
The goal of the Gene Ontology (GO) initiative is to provide a controlled vocabulary that
standardizes attributes assigned to genes and gene products to describe their roles in any
organism [19]. Attributes are related to three main categories: cellular component, biological
process and molecular function. Each of these categories is structured as a hierarchical
directed acyclic graph where terms are linked by either of the two relationships “is-a” or
“part-of”. Terms can have several parent terms and several child terms. Multiple databases
including PlasmoDB, the Plasmodium genome resource [22], have already annotated their
data with GO terms and provide references to support the annotations. This data is available
at http://www.geneontology.org together with tools to access and process the data.
4.2 Flux balance analysis
Flux balance analysis (FBA) is a commonly used method to investigate the metabolic capa-
bilities of cellular systems, since it allows to estimate unknown fluxes in metabolic networks
with respect to cellular constraints [130, 394, 138, 280, 125, 139, 218, 298, 365, 12, 84, 137,
359, 398, 337, 360, 404] (see Fig. 4.1 for illustration). Among others, FBA has been used
for metabolic engineering studies [387, 281], drug target prediction [233, 135, 279] as well as
growth prediction on different media [320, 522]. In contrast to kinetic modeling, no detailed
rate equations are required, predestining the method for large metabolic networks which
lack full kinetic characterization of all enzymes. Prerequisite is rather the stoichiometric
matrix S, which describes the number of metabolite molecules consumed and produced
by each reaction of the metabolic network, as well as knowledge about the cellular objec-
tive. The basis of FBA is the flux balance principle which assumes the system to be at
quasi steady-state, as biochemical reactions are typically much faster than changes in the
phenotype of a cell during growth or differentiation. Thus, the sum of fluxes producing a
metabolite equals the sum of fluxes consuming the metabolite:
Sv = 0
where v is the metabolic flux vector, containing internal metabolite fluxes as well as exchange
fluxes. The solution space of the resultant linear equation system is a high dimensional
flux cone, containing all flux configurations that are feasible at steady-state. Constraints
derived from thermodynamics and cellular environment conditions further restrict the so-
lution space. Organisms are thought to be optimized in the course of evolution. Therefore,
a biologically meaningful objective function, which is a linear function of fluxes, is applied
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Figure 4.1: Illustration of flux balance analysis. Given the stoichiometric matrix S of a
network and the steady-state assumption (A), a set of algebraic constraints on metabolic fluxes
v can be formulated. Additional constraints defining lower and upper bounds on each flux can
be inferred for example from thermodynamics. Usually the number of variables (unknown
metabolic fluxes) is larger than the number of equations (equals number of metabolites) for
the resulting linear equation system (B). Therefore, optimization is applied to identify a flux
distribution among all possible solutions, which is optimal with respect to a chosen criterion.
Here, flux v6, which corresponds to the secretion of a certain target metabolite, is maximized.
Given the set of constraints, a maximum flux value of 10 can be obtained for v6 if v1, v2 and
v5 are assigned to equal 10 (C).
to the set of possible solutions to identify a flux distribution that is optimal with respect to
the cellular objective. Maximization of biomass is one such target function that is assumed
to be suitable especially for microorganisms [523]. For eukaryotic cells such as hepatocytes,
for which reproduction is not the primary goal, cellular maintenance at minimal efforts has
been proposed as an alternative objective function [203]. Altogether this yields the following
FBA formalism:
min /max
v
cT v (objective function)
s. t.: Sv = 0 (steady-state assumption)
vmin,i < vi < vmax,i (constraints)
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where c is the vector of linear combination coefficients and vmin and vmax are the lower and
upper bounds on fluxes.
4.2.1 MinModes
Determining metabolic fluxes that are linked to certain cellular functions is often a difficult
task, especially in large metabolic networks. To avoid tedious experiments several structural
analysis concepts have been developed, including elementary modes and extremal pathways
[442, 449]. These methods explore for a given metabolic network all routes (modes) con-
verting substrates into output metabolites. The main disadvantage of these methods is the
large number of modes arising from combinatorial multiplicity when network size increases.
The concept of MinModes (see Fig. 4.2) is an approach based on flux balance analysis to
decompose flux distributions into a manageable number of functionally interpretable modes
[201]. A MinMode is defined as a minimal steady-state flux distribution that allows for
the production of a exactly one target metabolite, corresponding to a certain functional
requirement of the cell. The underlying assumption is that flux distributions are basically
superpositions of multiple MinModes with different relative intensities, which are reflected
in the coefficients of the linear combination. Thus, comparing the coefficients of two flux
distributions decomposed into MinModes unveils directly changes in cellular functions.
X
A B C
D E
H
GF
MinMode( X )
A B C
Figure 4.2: MinMode illustration. A MinMode is defined as a steady-state flux distribution which
is optimal with respect to the flux minimization principle (sum of non-zero fluxes is minimal)
and yields a single unit of the metabolite of interest. In the illustrated example network the
MinMode for metabolite X is indicated by the red line.
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4.3 Integrating gene expression data into flux calculations
Genome sequence analysis only reveals which metabolic reactions could possibly occur
within an organism, but not which reactions are actually active during a certain time point,
not to mention the quantitative contributions of each reaction. Objective functions repre-
senting cellular goals are supposed to drive flux balance analysis to the identification of true
flux distributions. However, considering that currently no organism is fully characterized,
suggests that proposed objective functions do not fully cover the true cellular objectives.
Furthermore, organisms might pursue different goals during different stages of their lifes-
pan and cells of multi-cellular organisms might even fulfill different tasks depending on the
tissue. A hint on the cellular status can be provided by gene expression experiments which
monitor the presence of gene transcripts during a certain time point and allow inferences
on the subsequent presence of corresponding enzymes. Integration of gene expression data
into flux balance calculations therefore has the potential to improve the modeling of cellular
metabolism.
4.3.1 GIMME algorithm
A straight forward way to integrate transcriptomic data into FBA was proposed by Åkesson
et al. [4]. The basic assumption is that if a gene is not expressed, the corresponding enzyme
is absent and thus the respective reaction is not catalyzed. In FBA calculations this is
implemented as additional constraints that keep fluxes through reactions to zero if enzymes
are not present, thereby reducing the feasible solution space. Improved predictions of the
metabolic behavior of yeast cells in batch cultures were obtained with this approach. Due to
the simplicity of this approach, no flux distributions can be predicted if required metabolic
functionalities can not be achieved without enzymes suggested by gene expression data to
be absent.
An approach solving this problem was published by Becker and Palsson [38] who named
their method GIMME (Gene Inactivity Moderated by Metabolism and Expression, see Fig.
4.3). Similar to the Åkesson approach, reactions with expression values below a certain
threshold are removed from the network, and an optimal flux distribution is sought that
meets the required metabolic functionalities. In case the problem is infeasible, optimization
is used to find the most consistent set of reactions to obtain a valid flux distribution:
min
∑
ci | vi |
s. t.: Sv = 0
ai < vi < bi
ci =
{
xcutoff − xi if xcutoff > xi
0 otherwise
where xi is the corresponding gene expression value and xcutoff a threshold above which
enzyme presence is assumed. The degree of inconsistency between predicted fluxes and gene
expression data is given by the value of the objective function.
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E1
E4
E5 obj = 10
E3
B D
E6
cell cannot achieve desired functionality (obj) without at least
one of the inactive reactions
A
C E
F
10
10
0
10
0 obj = 10
0
B D
10
Inconsistency Score
= 10*(10-9)
= 10
A
C E
F
0
10
10
0
10 obj = 10
10
B D
0
Inconsistency Score
= 10*(10-1) + 10*(10-2) + 10*(10-1)
= 260
Lowest Inconsistency Score
Expression above threshold
Expression below threshold
Enzyme Expression
E1 1
E2 30
E3 2
E4 9
E5 1
E6 40
T1 20
Threshold = 10
(A)
(B)
(C)
Figure 4.3: GIMME algorithm illustration. For the depicted metabolic network available gene
expression data is listed in the blue table (A). Applying a threshold of 10 to the expression
levels reveals that only enzymes E2, E6 and transporter T1 are active. Thus, the network can
not fulfill the objective of producing 10 units of metabolite F if only those reactions are allowed
to carry non-zero fluxes, where the level of corresponding gene transcripts is higher than the
chosen threshold. This objective can only be accomplished if either enzymes E1, E3 and E5
are assumed to be active as well (B) or enzyme E4 (C). The latter assumption yields a lower
Inconsistency Score, as the expression status of only one enzyme has to be changed, which
in addition is expressed at a level close to the threshold. Therefore, the GIMME algorithm
returns the flux distribution depicted in (C).
4.3.2 Shlomi approach
Shlomi et al. [465] presented a more sophisticated approach to predict tissue-specific meta-
bolic behavior on the basis of gene expression data and flux balance analysis. In contrast to
common FBA methods, no assumptions about cellular objectives are made. According to
the authors, hints on tissue-specific metabolic goals can rather be inferred from predicted
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metabolite uptake and secretion. The concept of the Shlomi approach is to maximize the
conformity of metabolic fluxes with the expression status of corresponding genes, but not
to insist on total agreement like the Åkesson approach in the case of unexpressed genes (see
Fig. 4.4). This takes into account post-transcriptional regulation, which arranges that on
the one hand certain gene transcripts are not translated into enzymatic proteins, while on
the other hand, certain gene transcripts present at almost undetectable levels are trans-
lated with high efficiency. The corresponding mixed integer linear programming problem is
formulated as follows:
max
v,y0,y1p,y1n
∑
i∈RNE
y0,i +
∑
i∈RE
(y1p,i + y1n,i) (4.1)
s. t.: Sv = 0 (4.2)
vmin ≤ v ≤ vmax (4.3)
vi + y1p,i(vmin,i − ) ≥ vmin,i, ∀i ∈ RE (4.4)
vi + y1n,i(vmax,i + ) ≤ vmax,i, ∀i ∈ RE (4.5)
vmin,i(1− y0,i) ≤ vi ≤ vmax,i(1− y0,i), ∀i ∈ RNE (4.6)
v ∈ Rm (4.7)
y0,i, y1p,i, y1n,i ∈ [0, 1] (4.8)
where v is the flux vector and S the stoichiometric matrix describing the topology of the
metabolic network. The steady-state assumption is ensured by (4.6). Thermodynamic
constraints restricting flux directions are imposed on the solution space by (4.7). Two
boolean variables (y1p,i, y1n,i) are introduced for reactions corresponding to expressed genes
(RE). Inequalities (4.8) and (4.9) enforce fluxes in forward or backward direction to be larger
than threshold  = 1 if the respective boolean variables are set to 1. Similar, inequality
(4.10) guarantees that reactions associated with unexpressed genes (RNE) do not carry any
flux if the boolean variables y0,i are equal to 1. The sum of these binary variables composes
the objective function that is sought to be maximized, in order to obtain flux distributions
that are consistent with corresponding expression profiles.
This approach was applied to predict tissue-specific metabolism for ten human tissues in-
cluding liver, brain and heart. Comparisons with available data sources for tissue specificity
of genes, reactions and metabolites showed significant correlations between predictions and
these data sets.
4.3.3 E-Flux algorithm
Very recently Colijn et al. proposed a novel method called E-Flux to infer the metabolic
status of a cell from gene expression profiles [96]. Like the approaches reviewed in the
previous sections, E-Flux extends the flux balance analysis concept. The basic idea is to
introduce lower and upper flux bounds for all reactions of a metabolic network as a function
of measured gene expression (see Fig. 4.5). Upper flux bounds are set to the expression
values of corresponding genes and are normalized with respect to the highest bound. If a
reaction is catalyzed by an enzyme complex, the minimum expression value of all complex
components is chosen as an upper flux bound. In case of isozymes catalyzing the same
reaction, the upper flux bound is set to the sum of all corresponding expression values.
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Figure 4.4: Illustration of the approach by Shlomi et al. to calculate metabolic
fluxes consistent with gene expression data. The example metabolic net-
work consists of four enzymes (E1-E4) and two transporters (T1, T2) whose corresponding
genes are all highly expressed except for those corresponding to E1 and T2. The predicted
steady-state flux distribution is indicated by light blue arrows. An alternative steady-state
flux distribution which assigns a non-zero flux to enzyme E2 would yield a lower objective
value, as the expression status of two enzymes/transporters (E1, T2) have to be changed in-
stead of one (E2). Therefore, gene transcripts corresponding to enzyme E2 are assumed to be
post-transcriptionally downregulated. Illustration adapted from [465].
Lower flux bounds are for all reversible reactions equal to the upper bounds multiplied
by -1 and for all irreversible reactions equal to 0. Thus, metabolic fluxes are constrained
to values between -1 and 1. If a reaction is associated with genes that are only sparsely
expressed, tight constraints are assigned to the fluxes, while flux constraints are looser, if
corresponding genes are highly expressed.
The E-Flux method was applied to the metabolism of the tuberculosis pathogen Mycobac-
terium tuberculosis, using as an objective function biomass maximization and mycolic acid
production, respectively. Several hundred gene expression experiments, comparing treated
cells with untreated cells, were considered to infer metabolic fluxes in treated cell lines and
control cell lines, respectively. The ratio of the maximal biomass production rate obtained
for treated cells and for untreated cells was then calculated to assess the impact of the
treatment on mycolic acid production. By this means several known inhibitors of mycolic
acid or fatty acid synthesis were correctly identified among the compounds used to treat
the bacterium and several yet unknown inhibitors and enhancers were predicted.
4.4 Network based drug target analysis
Identification of suitable drug targets represents the first step in the drug discovery pipeline
(see section 2.2). In general, a large number of cellular components come into consideration
for any particular disease. Experimental screening of all candidates is time consuming and
expensive. Therefore, computational methods that are able to prioritize a subset of these
candidates can help to reduce the number of targets that are experimentally tested and thus
reduce the costs, as computational methods are far less expensive than wet lab experiments.
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Figure 4.5: Illustration of the E-Flux method. Constraints imposed by the E-Flux method
on possible metabolic fluxes through the example network are illustrated by pipes surrounding
reaction arrows. The higher expression levels of corresponding genes are, the higher are the
upper limits on fluxes and thus the larger are the diameters of the pipes. (A) and (B) show the
flux rates obtained with the E-Flux algorithm for two different gene expression states (green:
low expression, red: high expression). When gene G1 is lowly expressed (A), reaction R1 is
restrained to carry a small flux. Although gene G2 is highly expressed, the flux through reaction
R2 cannot be higher than that through R1 due to the steady-state condition. However, if G1
has a similarly high expression level as G2 (B) R1 and R2 are both assigned to high flux values,
which in contrast to (A) exceed the fluxes through the moderately active reactions R3 and R4.
Illustration adapted from [96].
4.4.1 Metabolic control analysis
As outlined in section 2.2 components of a biological network are generally considered to
be good drug targets if they are essential for disease progression. Complete inhibition of
any of these components would result in disease attenuation. However, complete inhibition
of enzymes is difficult, since most drugs are designed as reversibly binding competitive sub-
strate analogs and thus can be supplanted by the substrate which accumulates upon enzyme
inhibition [101]. Therefore, drugs are more effective if they act on targets that have a large
influence on pathways even when inhibited only partially. Such targets can be identified
with the help of metabolic control analysis (MCA) [235, 195, 141], a mathematical frame-
work that was originally developed for metabolic networks, but has been extended to other
biological networks [210, 421]. So called flux control coefficients CJi and concentration
control coefficients CXi (see Fig. 4.6) quantify the impact of a network component i
(e.g., an enzyme) on the network flux J or component concentration X (e.g., metabolite
concentration), respectively, as follows:
CJi =
∂ ln J
∂ ln pi
∂ ln vi
∂ ln pi
, CXi =
∂ lnX
∂ ln pi
∂ ln vi
∂ ln pi
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with pi being a parameter such as enzyme concentration that is infinitesimally chang-
ed and vi being the enzyme rate. Changes of the parameter may shift the system from one
steady-state to another. Control coefficients basically relate the resulting relative changes
of steady-state fluxes (concentrations) to the relative activity changes of an enzyme with
all other enzyme activities being constant. The larger a control coefficient, the stronger is
the impact of an enzyme on the respective flux or concentration. A flux control coefficient
of 1 implies that changing the enzyme’s activity changes the steady-state flux in the same
proportion. The enzyme is thus a true rate-limiting enzyme. In ideal networks the sum of
all flux control coefficients equals 1 while all concentration coefficients sum up to 0 (sum-
mation theorem). Control coefficients are system properties and therefore change with the
status of a system.
MCA has been applied in drug discovery [76, 211] to suggest drug targets among others
for the treatment of cancer [97] and African sleeping sickness caused by the parasite Try-
panosoma brucei [26]. Glycolytic enzymes are assumed to be good drug targets in T. brucei,
since this pathway is the parasite’s only source for ATP. Bakker et al. proposed to choose
targets that have high flux control coefficients in the parasite, but low flux control coeffi-
cients in the host (differential control analysis), thus increasing selective inhibition. Four
glycolytic enzymes (aldolase, glyceraldehyde-3-phosphate dehydrogenase and phosphoglyc-
erate kinase and glycerol-3-phosphate dehydrogenase) were found to fulfill this criterion.
Drugs specifically designed to inhibit these enzymes in the parasite are therefore assumed
to have a large impact on parasite development, but few side effects on homologous host en-
zymes, due to lower binding affinities for host enzymes and lower influence of these enzymes
on the glycolytic pathway in the host.
S1
S3
S2v1 v2 v3
v4
?
?
?
Small
perturbation
S1 S2v1 v2 v3
? ?
Flux control coefficients CijJ Concentration control coefficients CijX
Small
perturbation
Figure 4.6: Flux control coefficients and concentration coefficients in metabolic
control analysis. The coefficients indicate the effect of changes in the activity of a
specific enzyme (dotted blue arrows) on steady-state fluxes or concentrations, respectively,
within a metabolic network.
The major downside of MCA is the requirement of a kinetic model for the system of
interest. Since kinetic data is not yet available for genome-scale networks, control coefficients
can only be calculated for well studied pathways. Furthermore, control coefficients are linear
approximations, thus overestimating larger variations in enzyme activities [447].
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4.4.2 Choke-point analysis
Choke-point analysis is a simple topology based approach to identify presumably essential
enzymes even in genome-scale metabolic networks. Choke-points are enzymes that either
uniquely consume or produce a certain metabolite (see Fig. 4.7). Inhibition of such an
enzyme likely results either in accumulation of metabolites, which is potentially toxic for
the cell, or in depletion of possibly essential metabolites, making the enzyme indispensable.
The essentiality of enzymes has been assessed with this method for several organisms [561,
401, 472, 136], revealing that choke-point analysis is able to detect validated drug targets.
Rahman et al. combined choke-point analysis with the concept of load-points, which
are network hot spots with a high number of k-shortest paths passing through, but a low
number of attached nearest neighbors [401]. Ranking choke-points according to their load is
assumed to prioritize biochemically important enzymes, since a high load indicates that an
enzyme connects a large number of metabolites via a shortest path. Another improvement
of choke-point analysis was proposed by Fatumo et al. who suggested an algorithm that
analyses whether all compounds downstream of a knocked-out reaction can be produced by
other pathways with an equal number of enzymatic steps as it would be possible with the
complete metabolic network [136]. Combination of this algorithm and choke-point analysis
resulted in a higher accuracy and precision for predicted drug targets.
A
B
C
D ECP2
CP1
CP3
Figure 4.7: Illustration of choke-points. The example metabolic network contains three choke-
points: CP1, because it produces a unique product; CP2, because it consumes a unique sub-
strate and CP3 because it both consumes a unique substrate and produces a unique product.
Illustration adapted from [561].
Choke-point analysis is a simple and fast method to predict drug targets, requiring only
the network topology as input, but no further experimental data. However, the method
tends to yield many false positives [561] and thus low accuracy, especially when the network
has a large periphery, which might be the case in incomplete networks.
4.4.3 Minimal cut sets
Another network topology based approach to detect components critical for metabolic func-
tioning is the concept of minimal cut sets (MCS) [256, 255], which is implemented in
the CellNetAnalyzer software available at http://www.mpi-magdeburg.mpg.de/projects/
cna/cna.html. A MCS is a irreducible set of network components whose removal will lead
to a failure in certain network functions such as the production of target metabolites (see
Fig. 4.8). Given a user defined objective function all MCSs of a metabolic network can be
computed on the basis of elementary flux modes (EM), which are minimal metabolic routes
through a network operating at steady-state [448, 449]. Any feasible steady-state flux dis-
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tribution can be represented by a linear combination of elementary flux modes. For each
EM that involves the objective reaction, a MCS contains at least one reaction active in this
EM. Thus, removing all reactions of a MCS from the metabolic network of interest ensures
that no feasible and balanced flux distribution through the network exists that involves
the objective reaction, as all EMs containing this reaction have vanished. The proposed
algorithm calculates MCSs by iteratively enlarging a set of reactions by adding a reaction
contained in an EM that involves the objective reaction, but does not contain any reaction
of the current set. When a set of reactions coveres all EMs corresponding to the objective
function and is not a superset of other sets with the same characteristic, the set is considered
to be a MCS.
A
P2
BR1
R2
R4
R5 R3
S P1
A
P2
BR1
R2
R4
R5 R3
S P1 A
P2
BR1
R2
R4
R5 R3
S P1
EM1 EM2
A
P2
BR1
R2
R4
R5 R3
S P1
EM3
A
P2
B
R1
R2
R4
R5 R3
S P1 A
P2
BR1
R2
R4
R5 R3
S P1
MCS1 MCS2
A
P2
BR1
R2
R4
R5 R3
S P1
MCS3
x x
x
x
Elementary Modes
Minimal cut sets (repressing production of P1)
(A)
(B)
(C)
Figure 4.8: Illustration of minimal cut sets concept. The metabolic network depicted
in (A) contains three elementary modes (B) of which two include the objective function R4
(highlighted by blue box). Based on these elementary modes the minimal cut sets which repress
the synthesis of P1, the product of the objective function, can be computed (C). Illustration
adapted from [255].
4.4.4 Gene knockout simulations based on flux balance analysis
Flux balance analysis methods allow to simulate the outcome of gene knockouts, when
information is available on nutrients that can be imported and target metabolites that
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are produced by a cell [131, 377]. In this context a reaction of interest is restricted to
carry no flux, while the network is asked to produce the target metabolites. This basically
corresponds to the calculation of MinModes for each essential metabolite without using the
reaction under examination. If the simulation is successful and a flux distribution satisfying
the constraints can be found, the tested reaction is assumed to be not essential, since the
network utilizes other reactions to fulfill the task. Otherwise, the enzyme catalyzing this
reaction can be considered as a putative drug target, as its inhibition would prevent the
synthesis of essential metabolites and thus cell maintenance or growth.
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Metabolic Network Reconstruction
5.1 Introduction
Living organisms apply a large set of biochemical reactions to fulfill a variety of cellular
tasks such as energy provision, maintenance of the cellular state, provision of precursors
for cellular reproduction and synthesis of signaling molecules. Most of the reactions within
these metabolic networks are catalyzed by genome encoded enzymes, since on the one
hand reactions may exhibit slow reaction kinetics, and on the other hand organisms are
able to regulate their metabolism by varying enzyme activities. Fig. 5.1 depicts a typical
metabolic network. Metabolites imported into the cell are either degraded by catabolic
reactions to yield energy and essential building block precursors, or they are utilized by
anabolic reactions to produce larger molecules such as biomass components. End products
fulfill their task within the cell or are excreted for further purposes. Metabolic networks
can be subdivided into metabolic pathways which consist of a series of reactions that
participate in the synthesis or degradation of the same metabolite. In the past, metabolism
was analyzed on this level of complexity, leaving out the crosstalk between pathways caused
by shared metabolites such as branch point metabolites and co-factors.
The reconstruction of genome-scale metabolic networks is guided by different data sources
[373]. Biochemical experiments provide the strongest evidence for the presence of enzymes
in an organism and thus corresponding biochemical reactions. Functionally annotated genes
that are homologous to the genomic sequence of interest give further clues on the structure
of a metabolic network. In addition, physiological knowledge on the capability of an organ-
ism to produce certain metabolites supports the assumption that respective biosynthesis
pathways are present. And finally, in silico simulations of known cellular behaviour may
identify missing reactions in case simulations fail due to gaps in the underlying metabolic
network. The confidence levels of these sources differ, being the highest for the direct bio-
chemical proof of enzyme functions and the lowest for reactions inferred by computational
simulations. Therefore, as long as not all reactions are experimentally verified and organ-
isms are fully characterized, reconstructed metabolic networks are still hypothetical and
subject to constant revision and extension.
Since the development of sequencing technologies, genomes of almost one thousand organ-
isms have been sequenced, and the sequencing of several thousand genomes is in progress
[272]. This deluge of sequenced genomes and the subsequent homology based gene anno-
tations allowed for the reconstruction of genome scale metabolic networks even for those
organisms for which direct biochemical information is scarce. Large scale metabolic net-
works are now available for organisms of all three major domains of the tree of life [12, 84,
125, 298, 174, 138, 359, 398, 139, 218, 443].
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Figure 5.1: Metabolic network scheme. Adapted from [162].
5.2 Metabolic network of P. falciparum
The basis for any genome scale metabolic network of P. falciparum constitute the functional
annotations of the genome sequence [161], which are catalogued in the PlasmoDB database
[22] (http://www.plasmodb.org/plasmo/home.jsp). Based on these annotations, as well
as literature knowledge, several groups have started to infer metabolic pathways occurring
in the parasite [170, 561, 241, 309]. However, none of these initiatives made the effort to
construct a functional, compartmentalized and consistent metabolic model.
The presented thesis aims at compiling a compartmentalized, comprehensive metabolic
network which is able to fulfill cellular functions known from the literature to occur in
P. falciparum. Therefore, data from multiple online resources have been integrated in the
assembly process. Biochemical reactions were gathered from the Malaria Parasite Metabolic
Pathways (MPMP) website (release of November 2007), the KEGG database (release of
February 2009), the BioCyc database (release of August 6th 2007 forP. falciparum 3D7),
the Reactome database (release of November 2007) and the BRENDA database (release of
January 2007).
KEGG reactions were considered as present in P. falciparum if genes of the parasite were
assigned via the KEGG Orthology (KO), a classification of orthologous and paralogous
groups of genes determined based on high sequence similarities to genes of known function.
Hagai Ginsburg kindly provided a list of genes and EC numbers corresponding to metabolic
pathways listed on the MPMP website. All KEGG reactions associated with these EC
numbers were checked for their presence in any of the pathways depicted at the MPMP
website and, where appropriate, added to the metabolic network. Similarly, all KEGG
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reactions associated with EC numbers that are annotated as present in P. falciparum by the
BRENDA database were included in the network. Furthermore, all reactions from BioCyc
that are listed in the PlasmoCyc subdatabase as well as all reactions from Reactome that
are inferred by sequence homology to occur in P. falciparum were added to the network.
As BioCyc reactions are mostly computationally inferred, reactions were removed that are
associated to pathways that are assumed to not be present in P. falciparum [171], except
for the chorismate biosynthesis pathway.
Since each resource uses individual identifiers for reactions and metabolites, it was neces-
sary to map the reactions onto each other. The KEGG identifiers were chosen as an overall
means of identification. P. falciparum reactions suggested by BioCyc and Reactome were
mapped to KEGG reactions via annotated genes or EC numbers. In case that way the
corresponding KEGG reaction was not found, involved metabolites were mapped to KEGG
metabolites either with the help of annotated ChEBI or PubChem identifiers, or, if such
cross-references were not available, the PubChem database was queried for matching syn-
onyms. The KEGG metabolite identifiers were then assembled to find the corresponding
KEGG reaction. For several reactions no matching KEGG reaction could be found by this
means. In such cases, the reaction equation translated to respective KEGG metabolites was
assigned with a new unique identifier starting with the letter ’Q’ followed by five digits in
the style of the KEGG identifiers.
Each reaction of the resulting metabolic network (see Fig. 5.2 and Table 5.1) was as-
signed to one of the following compartments: cytosol, nucleus, mitochondrion, apicoplast,
endoplasmic reticulum, or food vacuole. The default compartment for all reactions is the
cytosol. This assignment was overruled if a gene catalyzing a certain reaction is annotated
with another compartment by the Gene Ontology database. In addition, compartments were
reassigned when reactions are assigned by the MPMP website to a different compartment
or when corresponding genes contain signal sequences for the apicoplast or mitochondrion.
Information on transporters transferring metabolites between the different compartments as
well as between the host and the parasite, were mostly obtained from the MPMP website,
and in addition, from the Transport Classification database, BioCyc, and the Reactome
database.
Reactions were assumed to be irreversible if high Gibbs free energies were predicted or ob-
served [311, 312, 221]. In addition, pairs of synthesis and decay reactions were defined as irre-
versible in case the synthesis step involved energy-rich metabolites such as ATP or CoA con-
jugate but the decay step not, e.g.,Acyl-CoA + 1-Acyl-sn-glycero-3-phosphocholine
<=> CoA + Phosphatidylcholine and Phosphatidylcholine + H2O <=> 1-Acyl-sn-
glycero-3-phosphocholine + Fatty acid .
Organism Reactions
Trans-
porters
Meta-
bolites Genes
Compart-
ments
Plasmodium
falciparum
998 377 1,622 579 6
Human 349 88 566 1
erythrocyte
Table 5.1: Overview of assembled metabolic networks for P. falciparum and the
human erythrocyte.
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Figure 5.2: Overview of metabolic pathways present in P. falciparum.
5.3 Metabolic network of the human erythrocyte host cell
The best studied system among the host cells of P. falciparum is the human erythrocyte,
due to its reduced metabolic capacity and relatively simple availability. As predictions
are thought to improve when the parasite is integrated into its natural environment, the
metabolic network of this cell type was additionally compiled. For the human erythrocyte
multiple metabolic networks have been published that comprise the cell’s core metabolism,
including glycolysis, pentose phosphate pathway, glutathione metabolism and adenine nu-
cleotide metabolism (see [351, 217] and contained references). However, these networks lack
metabolic pathways providing cofactors such as thiamin diphosphate and pyridoxal phos-
phate that are required for full cellular functioning. Therefore, the metabolic network of
the human erythrocyte was assembled from available online resources to obtain a network
that is as complete as possible. As a main source served the enzyme database BRENDA
[82], from which all EC numbers were extracted that are assigned to enzymes of human
erythrocytes. Furthermore, the human red blood cell database [379], which catalogues the
proteome of human red blood cells, was queried for enzymes to complement those obtained
from BRENDA. Subsequently, the EC numbers were used to extract reactions from the
KEGG database. Transport processes listed at the Malaria Parasite Metabolic Pathways
website were added to the network and amended with transporters extracted from pri-
mary literature [222, 413, 529, 414, 433, 467, 257, 366, 43, 94, 260, 328, 61, 573, 15]. An
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overview of the network can be found in Table 5.1. The best studied system among the
host cells of P. falciparum is the human erythrocyte, due to its reduced metabolic capacity
and relatively simple availability. As predictions are thought to improve when the para-
site is integrated into its natural environment, the metabolic network of this cell type was
additionally compiled. For the human erythrocyte multiple metabolic networks have been
published that comprise the cell’s core metabolism, including glycolysis, pentose phosphate
pathway, glutathione metabolism and adenine nucleotide metabolism (see [351, 217] and
contained references). However, these networks lack metabolic pathways providing cofac-
tors such as thiamin diphosphate and pyridoxal phosphate that are required for full cellular
functioning. Therefore, the metabolic network of the human erythrocyte was assembled
from available online resources to obtain a network that is as complete as possible. As a
main source served the enzyme database BRENDA [82], from which all EC numbers were
extracted that are assigned to enzymes of human erythrocytes. Furthermore, the human
red blood cell database [379], which catalogues the proteome of human red blood cells, was
queried for enzymes to complement those obtained from BRENDA. Subsequently, the EC
numbers were used to extract reactions from the KEGG database. Transport processes
listed at the Malaria Parasite Metabolic Pathways website were added to the network and
amended with transporters extracted from primary literature [222, 413, 529, 414, 433, 467].
An overview of the network can be found in Table 5.1.
5.4 Consistency checks
The compiled metabolic networks of P. falciparum and the human erythrocyte were tested
for consistency to obtain functional metabolic models. In a first step, highly specific meta-
bolites such as α-D-Glucose were replaced by more general metabolites (D-Glucose), using
a manually compiled list of substitutions. Moreover, reactions containing generic terms like
’fatty acid’ were split into a set of reactions, each using a respectively more specific metabo-
lite (tetradecanoic acid, hexadecanoic acid, etc.). Next, generic reactions (A + n B → n C
+ D) were removed and reactions describing the synthesis or degradation of macromolecules
(A + B → A) were modified in such a way that one metabolite does not occur on both sides
of a reaction equation. Finally, reaction duplets that were already present in the original
data or were generated by the consistency procedure were deleted.
Up to this point, the metabolic network is basically just a set of accumulated reactions. To
transform the network into a fully operative model, flux balance simulations were conducted
with regard to the producibility of important biomass precursors such as lipids, nucleotides,
amino acids, carbohydrates, and cofactors (see Table 5.2). In this context MinModes [201]
were calculated for each of these metabolites, which are basically minimal steady-state flux
distributions that allow for the production of a certain metabolite. In case no MinMode
could be calculated, i.e., no path exists that converts external nutrients into the metabo-
lite of interest, precursors of the metabolite (as defined by metabolic maps of KEGG and
MPMP) were consecutively checked with respect to their producibility until one was found
that is producible, thus revealing missing reactions and transporters. Endproducts and
intermediates of pathways known from the literature to occur in P. falciparum, e.g., glycol-
ysis, pentose phosphate cycle, hemoglobin degradation and glutathione conjugate export,
were examined in the same way. This process revealed that mostly intracellular transporters
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were missing in the network. Reactions that had to be added include tRNA ligases in the
mitochondrion and apicoplast, DNA and protein synthesis reactions, and the biosynthesis
of unsaturated fatty acids.
Table 5.2: Essential metabolites for parasite and erythrocyte. Cellular compart-
ments: [n] = nucleus, [a] = apicoplast, [m] = mitochondrion, [er] = endoplas-
mic reticulum, [v] = food vacuole. The first nine metabolites represent pseudo-
metabolites, which are needed to test respective reactions.
Metabolite Parasitic stages where assumedto be essential
active-cytochrome-c-reductase[m] all stages
active-glutathione-reductase all stages
active-glutathione-transferase all stages
active-glyoxalase-II all stages
active-SAH-hydrolase all stages
active-superoxide-dismutase all stages
active-superoxide-dismutase[m] all stages
active-superoxide-dismutase[v] all stages
active-thioredoxin-reductase all stages
ATP all stages
cAMP all stages
Cardiolipin all stages
Cholesterol all stages
CoA all stages
Diacylglycerol all stages
DNA[a] all stages except: merozoite,
mosquito midgut sporozoite,
mosquito salivary gland sporozoite,
gametocyte
DNA[m] all stages except: merozoite,
mosquito midgut sporozoite,
mosquito salivary gland sporozoite,
gametocyte
DNA[n] all stages except: merozoite,
mosquito midgut sporozoite,
mosquito salivary gland sporozoite,
gametocyte
eIF5A-precursor-hypusine all stages
FAD all stages
Fe-S protein[a] all stages
Fe-S protein all stages
Glycoprotein all stages
GPI-protein[er] all stages
Heme[m] all stages
Hemozoin[v] only blood stages
Continued on next page
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Table 5.2 – continued from previous page
Metabolite Parasitic stages where assumedto be essential
Hexadecanoic acid all stages
H+-pumped[m] all stages
Isopentenyl diphosphate all stages
mRNA[a] all stages
mRNA[m] all stages
mRNA[n] all stages
NAD+ all stages
NADP+ all stages
Octadecanoic acid all stages
Phosphatidate all stages
Phosphatidylcholine all stages
Phosphatidyl-D-myo-inositol all stages
Phosphatidylethanolamine all stages
Phosphatidylserine all stages
Protein[a] all stages
Protein[c] all stages
Protein[m] all stages
Protein-C-terminal-S-farnesyl-L-
cysteine-methyl-ester
all stages
Protein-N6-(lipoyl)lysine[a] only late liver stages
Protein-N6-(lipoyl)lysine[m] all stages
Pyridoxal phosphate all stages
S-adenosyl-L-methionine all stages
S-geranylgeranyl-protein all stages
Sphingomyelin all stages
Tetrahydrofolate all stages
Thiamin diphosphate all stages
Triacylglycerol all stages
Ubiquinone[m] all stages
(9Z)-Hexadecenoic acid all stages
(9Z)-Octadecenoic acid all stages
(9Z,12Z)-Octadecadienoic acid all stages
5.5 Discussion
Genome-scale metabolic reconstructions are typically derived from genome annotations
which are coupled with data from comprehensive databases about enzymes and metabolic
pathways such as EXPASY and KEGG. Primary literature is then used to complement
the initial reconstruction. This process of validating each individual reaction of a recon-
structed metabolic network is very time consuming and may easily demand several man-
years. Therefore, the presented metabolic network of P. falciparum was instead compiled
from preprocessed data generated by several scientific groups based on primary literature
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and computational inferences. Consistency checks and flux balance simulations identified
gaps in pathways and facilitated the development of the first functional compartmentalized
metabolic network of P. falciparum.
Most metabolic networks previously reconstructed do not consider the environment of
an organism in terms of other organisms. The first multispecies metabolic network was
published by Stolyar and colleagues [486] which represents syntrophic interactions among
the anaerobic microorganisms Desulfovibrio vulgaris and Methanococcus maripaludis. Con-
ducted simulations accurately predicted metabolic fluxes and the relative abundance of the
two organisms. So far, no efforts have been made to computationally analyze the metabolic
interactions between P. falciparum and its host cells. Hence, the compiled metabolic net-
works of P. falciparum and the human erythrocyte present a good opportunity to explore
the exchange of metabolites during the blood stage of parasite development.
Reconstructed metabolic networks have been proven useful for multiple applications, in-
cluding interpretation of high-throughput data, guidance of metabolic engineering, hypoth-
esis testing and analysis of network properties (see [361] and references therein). In general,
the quality of results derived from such reconstructions depends heavily on the informa-
tion used to attain them. For example, about 50% of the predicted genes in P. falciparum
are not annotated yet, suggesting that the compiled metabolic network is not complete.
Furthermore, as pointed out in [171], most of the dababases (BioCyc, KEGG, Reactome)
infer metabolic pathways computationally which results in predictions where actually only
one or two enzymes of the pathway are associated with genomic sequences and therefore
very likely do not occur in the parasite. To cope with this problem, those pathways were
removed that are suggested by [171] to be not present in P. falciparum. Moreover, it is
likely that in the future genes will be discovered in the genome of the parasite that encode
for missing enzymes thereby filling current annotation gaps of the metabolic network. But
still, as not every single reaction has been validated in the network compilation process, it is
likely that fractions of the metabolic network are not correct which may influence simulation
outcomes. However, compared to currently available reconstructions of the P. falciparum
metabolism, the network presented here is not only the most comprehensive one, but has
also been proven to be functional, hence providing a basis for further analysis.
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Predicting life cycle specific metabolism
6.1 Introduction
Reconstructions of metabolic networks as presented in the previous chapter provide the basis
for predictions on the metabolic behavior of a cell. Not only local, but also system-wide
effects of cellular perturbations like varying environments or inhibition of certain enzymes
can be assessed with the help of such large-scale networks [361].
The metabolism of P. falciparum has been analyzed in a network based approach by Yeh et
al. [561] and Fatumo et al. [136]. Yeh and colleagues developed PlasmoCyc, a sub-database
of BioCyc, which contains P. falciparum related metabolic reactions annotated with genomic
sequences. Putative drug targets were identified in the resulting metabolic network by choke-
point analysis. Metabolic data from PlasmoCyc was also analyzed by Fatumo et al. with
respect to essential enzymes. The applied breadth first search approach inspects whether
metabolites downstream of a blocked reaction are producible via alternative routes and thus
the reaction is dispensable. Combined with choke-point analysis this approach improves
the precision of the prediction results compared to choke-point analysis alone. However,
drug targets proposed by these approaches are presumably of limited quality, since they are
derived from metabolic networks that are not further processed using additional information
such as cellular compartments and transport processes. Moreover, they did not consider
the different life cycle stages of the parasite, during which the metabolism might vary due
to different cellular environments.
As outlined in section 4.2 flux balance analysis (FBA) is a commonly used computational
method to gain insight into the metabolic capabilities of a cell. Several extensions of this
methodology have been proposed that integrate high-throughput data in order to obtain
more realistic metabolic flux predictions for a particular cellular condition [4, 38, 465, 96,
417]. These approaches add constraints to the basic FBA formalism that reflect gene or
protein expression, which, in contrast to metabolite levels, are available on genome-scale
for multiple organisms. For example, reactions were constrained to a flux value of zero if
expression of the corresponding transcript or enzyme could not be detected [4, 417, 96]. Less
strict approaches do not exclude such reactions, but rather seek flux distributions which are
most consistent with expression data [465, 38].
This work intends to deduce stage-specific metabolism for all stages of the life cycle
of P. falciparum with the help of flux balance analysis and gene expression profiles. For
this purpose the approach developed by Shlomi et al. [465] was adapted and applied to
the assembled metabolic network under consideration of gene expression profiles measured
during different life cycle stages.
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6.2 Applied gene expression profiles
Large-scale gene expression profiles are available for the blood stage of P. falciparum as
well as the mosquito stage. However, the liver stage in the human host is experimentally
difficult to assess and therefore gene expression data covering this stage in P. yoelii, a close
relative of P. falciparum causing malaria in rodents, were additionally considered in this
study. Gene expression is assumed to be sufficiently similar in these two Plasmodium species,
justifying the utilization of P. yoelii data to infer metabolic fluxes in P. falciparum. Gene
expression data has been gathered from five publications (see Table 1): (a) a genome-scale
transcriptome analysis of P. falciparum covering the intraerythrocytic developmental cycle
(IDC) by Bozdech et al. [59] (see section 3.1.1), (b) a genome-scale transcriptome analysis
by Le Roch et al. [419] examining the blood stage and the mosquito stage of P. falciparum
(see section 3.1.2), (c) a cDNA library obtained from liver stage expression analysis of the
rodent malaria pathogen P. yoelii by Sacci et al. [427] (see section 3.1.3), (d) a data set
from Tarun et al. [501], which includes samples extracted from P. yoelii during the liver
stage, the mosquito stage and the blood stage (see section 3.1.4) and (e) a genome-scale
transcriptome analysis by Daily et al. of 43 samples derived from the blood of P. falciparum
infected patients which contain mostly ring stages of the parasite [112] (see section 3.1.5).
In total, 110 gene expression samples were analyzed.
In a first step, the accordance of these data sets was checked with regard to corresponding
stages. For this purpose the expression status was determined for each gene of every expres-
sion sample. For the Le Roch data set the same parameter cutoffs were applied as mentioned
in [419] (thermocycling treatments data): expression level E > 10 and likelihood of gene
absence (calculated by the match-only integral distribution algorithm) logP < −0.5. Genes
covered by the Bozdech and Tarun data sets were considered to be expressed if the corre-
sponding signal-to-noise ratio (s2n = (mean(FG)−mean(BG)) / std(BG), with FG being
the pixel signal intensity resulting from specific hybridization and BG being the background
intensity caused by non-specific binding), is greater or equal to a threshold. Signal-to-noise
ratios were extracted from the raw data, averaged over all replicates and normalized using
quantile normalization [54]. Applying a too low or too high threshold results in almost all
genes being expressed or silenced, respectively. For the Bozdech data set the threshold t
was chosen in such a way that the average Euclidean distance between the binary expression
values
expr (g | t) =
{
0 if gene g is silent given threshold t
1 if gene g is expressed given threshold t
is maximal for non-consecutive pairs of samples and minimal for consecutive pairs:
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argmax
t
n−2∑
i=1
n∑
j=i+2
√
m∑
k=1
[expr (gi,k | t)− expr (gj,k | t)]2
n−2∑
i=1
n∑
j=i+2
1︸ ︷︷ ︸
avg. Euclidean distance between non-consec. pairs
−
n−1∑
i=1
√
m∑
k=1
[expr (gi,k | t)− expr (gi+1,k | t)]2
n− 1︸ ︷︷ ︸
avg. Euclidean distance between consec. pairs
with n being the number of samples per set, m being the number of genes per sample and
gi,k being the kth gene in the ith sample.
A threshold of 17 turned out to be optimal. This approach could not be applied to the
Tarun set, since the time span between extractions of samples is much larger. Instead, the
signal-to-noise ratio threshold was set to 25 which yielded largest similarity between Tarun
samples and corresponding Le Roch samples. As the Sacci data set is a cDNA library that
captures mRNA present at a certain time point, all genes of the library were accounted
as expressed. For the Daily samples a gene expression signal cutoff of 139 yielded largest
similarity between samples of cluster 2 (active growth) and ring stage expression samples
of the Le Roch set and was therefore used to determine expression in Daily samples.
Similarities and differences between the expression patterns of the individual life cycle
stages were then assessed with a simple and intuitive distance measure, the normalized
Hamming distance:
dist(i, j) = | Ei ∩ Sj | + | Ej ∩ Si || Gi ∩Gj |
with Ei, Si and Gi being the set of expressed, silenced or all analyzed genes, respectively,
in sample i. The numerator equals the sum of genes with different expression status, while
the denominator equals the total number of common genes in two samples. The resulting
Hamming distance matrix for all gene expression sample pairs is shown in Fig. 6.1.
The distance matrix reveals that samples of the same data set covering consecutive time
points tend to be more similar compared to those covering non-consecutive time points,
especially samples of the Bozdech or the Le Roch data set. Furthermore, similar gene
expression patterns can be observed for samples of different data sets that correspond to
the same life cycle stage, e. g. Le Roch ring stage samples and Bozdech samples extracted
during hour 1 to 20 after erythrocyte infection. In addition, the distance matrix agrees
well with the observation by Daily et al. that the in vivo ring stage expression samples
can be ascribed to three clusters [112]: starvation response accompanied by metabolism
of alternative carbon sources (cluster 1), active growth based on glycolytic metabolism
(cluster 2) and environmental stress response (cluster 3). The distance matrix confirms
that samples of the same clusters are more similar in terms of expressed enzymes. Only a
fraction of cluster 3 samples exhibits similarity to cluster 1 samples. Moreover, it shows that
samples of cluster 2 are similar to those samples of the Bozdech and Le Roch data sets which
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in vivo blood
Tarun &
Le Roch
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Sacci
Tarun & Le Roch & Bozdech
Daily
Cluster 1 Cluster 2 Cluster 3
Figure 6.1: Normalized Hamming distance matrix for gene expression samples. In
order to compare the gene expression profiles of the different time points, normalized Hamming
distances have been calculated as described in the text for each pair of gene expression samples.
The darker the color of a matrix entry, the lower is the corresponding Hamming distance.
Sample labels are composed of the sample abbreviation (see Table 1) and the number of
expressed genes.
correspond to early or very late blood stages. In general, Hamming distances are larger when
samples belong to different data sets. This can be ascribed to one or more of the following
issues (i) different methods have been used to analyze gene expression (microarray analysis
vs. cDNA library), (ii) experiments are conducted with different organisms (P. falciparum
vs. P. yoelii) and (iii) for the individual data sets different criteria have been applied to
classify genes as absent or present.
6.3 Gene expression data mapped onto metabolic pathways
Mapping gene expression data onto metabolic networks may uncover active pathways for
each stage and metabolic differences between the individual life cycle stages. For this
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Figure 6.2: Bozdech gene expression samples mapped onto metabolic pathways.
Mapping gene expression data onto metabolic networks may uncover active pathways for each
stage as well as metabolic differences between the individual life cycle stages. For this purpose,
the ratio of expressed genes per KEGG pathway (# expressed genes / # of pathway associated
genes with available expression data) was calculated for each Bozdech gene expression sample.
The darker the color of a matrix entry, the lower is the ratio. Clusters of pathways with similar
patterns of expressed genes during the individual life cycle time points were calculated with
the built-in function hclust (’average’ method) of the statistics software R (colored bars).
purpose, the ratio of expressed genes per pathway (as defined by KEGG) was calculated for
each gene expression sample (see Fig. 6.2 - 6.5) and pathway clusters were determined.
Three pathway clusters can be identified for the Bozdech and the Le Roch data sets,
which roughly correspond to each other (see green, blue, and yellow bar in Fig. 6.2 and Fig.
6.3). The green clusters, which have 10 pathways in common (e. g. glycolysis, glycerophos-
pholipid metabolism and porphyrin metabolism), contain pathways where only a fraction
of pathway associated genes are expressed during the IDC with a maximum of expressed
genes during late trophozoite and early schizont stage. Pathways associated with the blue
clusters (common pathways: fatty acid biosynthesis, lipoic acid metabolism, vitamin B6
metabolism and one carbon pool by folate metabolism) show gene expression almost exclu-
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Figure 6.3: Le Roch gene expression samples mapped onto metabolic pathways.
See caption of Fig. 6.2.
sively during late trophozoite and early schizont stages of the IDC, while those of the yellow
clusters (common pathways: pentose phosphate pathway, inositol phosphate metabolism)
exhibit many expressed genes during all phases of the intraerythrocytic developmental cy-
cle. Notably, during the gametocyte stage (Le Roch data set) a high number of genes are
expressed in all pathways and in contrast only few genes during the invasive stages (Le
Roch data: sporozoite, merozoite). Pathway clusters as described above for the blood stage
are not as apparent for the Tarun data, since this stage has not been analyzed as detailed.
Nevertheless, certain pathways group together as seen for the Bozdech and Le Roch data
sets (see colored bars in 6.4). Daily and coworkers found that their ring stage expression
samples can be divided into three clusters: starvation response accompanied by metabolism
of alternative carbon sources (cluster 1), active growth based on glycolytic metabolism (clus-
ter 2) and environmental stress response (cluster 3). These clusters can be found as well
when expression samples are mapped to metabolic pathways as shown in 6.5. In samples of
cluster 1 almost all enzymes are expressed in each of the considered pathways, suggesting
that required metabolites cannot be obtained in sufficient amounts from the host and thus
the parasite has to activate all possible pathways in order to obtain these metabolites. In
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Figure 6.4: Tarun gene expression samples mapped onto metabolic pathways.
See caption of Fig. 6.2.
contrast, less enzymes are expressed in samples corresponding to cluster 2. Here, enzymes
of sugar metabolism related pathways like glycolysis, pentose phosphate pathway and glyc-
erophospholipid metabolism (blue bar) are mostly activated. Similar expression patterns
can be observed for cluster 3 samples. However, more enzymes are expressed in certain
pathways such as fatty acid synthesis, thiamine metabolism and ubiquinone biosynthesis
(pink bar).
In general, the majority of metabolic pathway genes is expressed during starvation (Daily
data) or late trophozoite and early schizont stage where reproduction of biomass is at its
peak [366]. Pathways showing similar patterns of activation and suppression are presumably
co-regulated. Especially in the case of purine and pyrimidine biosynthesis this is plausible,
since both nucleotide types are needed in large amounts at the same time during DNA
replication and mRNA synthesis. Likewise the expression of genes associated with fatty
acid biosynthesis, pyruvate metabolism, and lipoic acid metabolism seems to be coupled,
since only few genes are expressed during blood stages but significantly more during liver
stages. Most of the reactions assigned to these three KEGG pathways are assumed to
take place in the apicoplast and are linked to each other. When fatty acid demand is fully
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Cluster 1
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Cluster 3
Figure 6.5: Daily gene expression samples mapped onto metabolic pathways.
See caption of Fig. 6.2.
satisfied by import, which is suggested for the blood stage by findings of Vaughan et al. [526],
neither the precursor acetyl-CoA (pyruvate pathway) nor lipoic acid, a cofactor of pyruvate
dehydrogenase catalyzing acetyl-CoA synthesis, are needed within the apicoplast. Thus, it
seems reasonable that these three pathways, which cluster together when considering the
Bozdech dataset, are co-regulated.
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6.4 Metabolic flux predictions for different life cycle stages
Gene expression data give an impression of the metabolic status of a cell, as has been
shown in the previous section. However, gene expression data alone are not sufficient to
deduce metabolic fluxes. Simply assuming a correlation between gene expression levels and
metabolic fluxes is not appropriate, since it has been shown that neither mRNA levels and
protein levels always correlate well [181, 214, 176, 86] nor enzyme levels and corresponding
flux rates of catalyzed reactions [134, 504]. Furthermore, expression data is not always
available for all genes of interest, or in some cases, there are no genes assigned to metabolic
reactions at all, if they are rather inferred from metabolic context than based on direct
biochemical evidence. In addition, from gene expression data alone no information can be
gained with regard to which nutrients are imported into the cell and which metabolites are
secreted. Flux balance approaches provide a means to predict flux distributions despite such
obstacles. Flux values can be predicted even for those reactions where no gene expression
data is available, as fluxes are not independent due to the assumed steady-state condition,
which requires the sum of fluxes producing a metabolite to equal the sum of fluxes consum-
ing it. A reasonable objective function describing the cellular goals is essential to obtain
meaningful flux distributions with FBA. In the case of P. falciparum the overall goal is
reproduction, and thus biomass production. At the same time the parasite has an interest
to keep its host cell alive for the period of replication which sets an upper limit on the
replication rate. Depending on how well the organism of interest is already studied, the
objective function might neglect certain metabolically important issues, e.g., a metabolite
essential for reproduction that has not been noticed yet. On this account, an approach is
applied here that combines FBA and gene expression information to calculate flux distribu-
tions for the different parasitic life cycle stages. The integration of expression data ensures
that metabolic aspects not captured by the objective function are nevertheless represented
in the calculated flux distributions.
Flux distributions were predicted for the different parasitic life cycle stages based on the
method proposed by Shlomi et al. [465], which maximizes the number of reactions whose
activity is consistent with the expression state of corresponding genes. The original method
by Shlomi has several limitations, though: synthesis of metabolites needed for growth is
not guaranteed; reactions of low confidence are treated the same as those with annotated
genes; in order to maximize the objective function, all reactions catalyzed by the same gene
product are sought to be active simultaneously in case the gene is expressed; furthermore, no
limits are set on available nutrients. Therefore, this approach was modified in several ways
(see Fig. 6.6): (a) Constraints were added to ensure the production of important biomass
precursors such as phospholipids, which are needed for parasite reproduction (see Table
5.2). These target metabolites might vary depending on the stage covered by the given
gene expression sample. DNA synthesis is important for stages aiming at reproduction, like
trophozoites. In contrast, for invasive forms of the parasite (sporozoite, merozoite, etc.)
this is not an issue and therefore not considered in flux calculations corresponding to these
stages. Furthermore, blood stages need to incorporate heme from hemoglobin degradation
into hemozoin molecules in order to prevent intoxication and cell lysis. This makes hemozoin
a target metabolite for these stages, but not for liver or mosquito stages where hemoglobin
is not present. Targeted deletions of critical fatty acid synthesis enzymes in P. yoelii and
P. falciparum suggest that fatty acid synthesis in the apicoplast is only essential during late
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liver stage [526]. This implies that pyruvate dehydrogenase (PDH), which provides fatty
acid synthase with acetyl-CoA, is not essential during any other stage and thus lipoate, a
cofactor of PDH, is as well dispensable in the apicoplast. Since PDH is the only enzyme
in the apicoplast that requires lipoate, lipoate biosynthesis is demanded in this organelle
only during late liver stage. (b) For all reactions whose existence is not supported by
genome annotations, boolean variables (y2,i) and constraints were introduced that keep
these reactions inactive if the respective variable is set to 1. This is useful as especially
data from the BioCyc database contain reactions without any associated gene that are
nevertheless declared to be present in P. falciparum to fill gaps in pathways. (c) In contrast
to the original Shlomi approach, the modified method does not seek all reactions catalyzed
by the same enzyme to be simultaneously active if the respective gene is expressed. As the
objective function of the approach proposed by Shlomi et al. maximizes the sum of boolean
variables that represent reaction activity, higher objective function values are obtained if
non-zero fluxes are assigned to all reactions corresponding to expressed genes. However,
this might not always be appropriate. Therefore, for each expressed gene a boolean variable
(y3,i) and constraints were added, ensuring that at least one of the reactions associated to
an expressed gene has to carry a non-zero flux in case the respective variable is set to 1.
Replacing variables y1p and y1n (see section 4.3.2 for more details of the Shlomi approach) in
the objective function with this variable type avoids that all reactions catalyzed by the same
expressed enzyme are sought to be active at the same time to further optimize the objective
function value. (d) With respect to the restrained access of the parasite to nutrients of
the host, the network is forced to fulfill its tasks with a minimum amount of externally
supplied metabolites by subtracting the absolute flux values through the parasite’s plasma
membrane transporters from the objective function value. The corresponding mixed integer
linear program reads as follows:
max
v+,v−,y0,y2,y3
∑
i∈RNE
αy0,i +
∑
i∈RNG
βy2,i +
∑
i∈GE
γy3,i −
∑
i∈T
δv+i (6.1)
s. t.: Sv = 0 (6.2)
vmin,i ≤ v ≤ vmax,i (6.3)
vi ≥ 1, for all target fluxes (6.4)
vi + y1p,i(vmin,i − ) ≥ vmin,i, ∀i ∈ RE (6.5)
vi + y1n,i(vmax,i + ) ≤ vmax,i, ∀i ∈ RE (6.6)
vmin,i (1− y0) ≤ vi ≤ vmax,i (1− y0) , ∀i ∈ RNE (6.7)
vmin,i (1− y2) ≤ vi ≤ vmax,i (1− y2) , ∀i ∈ RNG (6.8)
y3,i − y1p,r(i) ≥ 0, ∀i ∈ GE (6.9)
y3,i − y1n,r(i) ≥ 0, ∀i ∈ GE (6.10)
y3,i ≤
∑
y1p,r(i) +
∑
y1n,r(i), ∀i ∈ GE (6.11)
v = v+ − v− (6.12)
y0, y1p, y1n, y2, y3 ∈ [0, 1] (6.13)
v+, v− ≥ 0 (6.14)
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Within the solution space, which is defined by (6.2)-(6.14), a flux distribution is sought
that maximizes the objective function given in (6.1). α denotes the reward for setting the
fluxes of reactions to zero that correspond to unexpressed genes (RNE), β represents the
reward for assigning a zero flux to such reactions that are not associated with any gene
(RNG), γ denotes the reward for having a non-zero flux through any reaction assigned to
an expressed gene (GE), while δ is the penalty for forward fluxes v+ through parasitic
plasma membrane transporters (T ) importing external metabolites. The variables were set
as follows: α = 2, β = 0.1, γ = 1, and δ = 0.5. Inequalities (6.5)-(6.7) are the same as
in [465] with  = 1 and (6.8) is analogous to (6.7) to obtain a zero flux through reactions
without associated genes. The subsequent inequalities (6.9)-(6.11) ensure that if a binary
variable of type y3 is set to 1, at least one of the corresponding variables of type y1 have
to equal 1 as well. Matching variables y1 and y3 are identified via function r(i) that maps
a gene onto a set of reactions that are catalyzed by the gene product. Biomass production
is ensured by (6.4), which requires effluxes of at least one molecule of the respective target
metabolites through system boundaries.
The modified approach was applied to each of the gene expression samples extracted from
different time points of parasite development (see Table 1) to predict respective metabolic
fluxes during these time points. In order to compare the resulting flux distributions for the
individual time points, normalized Hamming distances were computed for all flux distri-
bution pairs (see Fig. 6.7). In general, the calculated flux distributions are more similar
to each other (max. Hamming distance: 0.188) than the corresponding gene expression
samples (max. Hamming distance: 0.718). However, similarity patterns as observed for
the gene expression data are also detectable for the flux profiles. For example, flux profiles
corresponding to consecutive time points during the blood stage are more similar than those
of non-consecutive time points (see Bozdech data; trophozoite stage vs. schizont) and flux
profiles corresponding to in vivo expression profiles of the same cluster tend to be more
similar than those of different clusters.
As experimental data on intra-parasitic metabolic fluxes are not available, the plausibility
of calculated flux distributions was checked by comparing predicted exchange fluxes between
host and parasite with available experimental observations.
6.5 Metabolite exchange with host
During its life cycle, P. falciparum is exposed to different environments and has to deal
with different nutrient supply. It has been shown for Trypanosoma brucei that the parasite
is able to remodel its metabolism depending on the available carbon sources [104]. It is
very likely that P. falciparum utilizes likewise varying parts of its enzyme equipment as
a function of available nutrients, which results in varying sets of metabolites transported
through the parasite’s plasma membrane during the individual developmental stages.
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Figure 6.6: Illustration of presented flux balance approach to predict life cycle
specific metabolism. Given the gene expression data (blue table) flux distributions
within the present example metabolic network (red arrows) can be inferred for time points t1
and t2 as depicted in (A). However, neither flux direction nor flux strength can be deduced
from gene expression alone. The set of all possible flux distributions that are conform with
the gene expression data can be reduced by knowledge about target fluxes such as biomass
production (a). Reactions that are not supported by genome annotation might represent errors
in the network assembly. Therefore it is desirable to prevent the usage of such reactions in
calculated flux distributions (b). An enzyme or a transporter that is able to process different
metabolites does not necessarily convert all substrates at same rates. If one reaction product
is not converted further by subsequent enzymes, it accumulates and as a consequence the net
production rate is close to zero, even if the gene is expressed and substrate is available (c). The
flux solution space can be narrowed down further, when assuming that biomass production
is achieved with a minimal amount of nutrients (d), which are of varying availability (e).
Gene products can be present within a cell, even when the gene transcript is not detectable,
as proteins appear later than the corresponding mRNA and protein degradation might be
delayed compared to mRNA degradation. Considering proteins to be present whose transcript
was detectable during a previous time point (f) presumably reflects the actual cellular status
better than taking only the current transcription snapshot into account. The flux distribution
calculated by the flux balance approach, which incorporates all these issues, is shown in (B).
Fig. 6.8 gives an overview of imported (red) and secreted (green) metabolites during
the individual life cycle stages, as predicted with the above described FBA method when
considering only the metabolic network of the parasite, without any further information
about the parasite’s environment. Glucose, the main energy source for P. falciparum during
the IDC, is converted via glycolytic enzymes to lactate, which is then excreted [463]. This
phenomenon is recovered by the simulations for multiple time points. Strikingly, for many
stages amino acids are predicted to be exported, which does not seem beneficial for protein
biosynthesis. In fact, the parasite digests up to three quarters of the host hemoglobin during
the IDC to provide amino acids for protein synthesis, to gain space in the host cell for further
growth [265] and to maintain the osmotic stability of the host cell [284]. Excess amino acids
not incorporated into the parasite’s proteome are exported out of the infected host cell
[569] and is therefore in accordance with the predictions. Experiments have shown that P.
falciparum relies on exogenous supply of isoleucine, the only amino acid that is not present
in hemoglobin [289]. For all time points covered by gene expression samples isoleucine
uptake has been correctly predicted. Moreover, in concordance with experiments by Kirk
and Saliba [251], coenzyme A precursor pantothenate is imported in all the simulations.
According to the predictions, the parasite satisfies its demand for NAD+ precursors mostly
with the import of nicotinamide, but also with nicotinate import, which is conform with
experimental findings [366] that suggest P. falciparum to be dependent on exogenous supply
of these metabolites. The parasite possesses an antioxidant defense system, which involves
glutathione to eliminate peroxides and toxic substances. Resulting glutathione disulfate and
glutathione conjugates are subsequently either regenerated or removed from the cell [344].
All predicted flux distribution correctly suggest the export of glutathione conjugates.
However, there are predicted transport processes that are not conform with literature
knowledge. For example, phosphate is mostly predicted to be exported, while it is reported
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Figure 6.7: Normalized Hamming distance matrix for calculated flux distribu-
tions. Flux distributions have been predicted with the developed flux balance approach
for each time point of the parasite’s life cycle for which a gene expression profile exists. Sim-
ulations were conducted considering only the metabolic network of the parasite without any
further constraints reflecting the parasite’s environment and without considering the expression
status of genes during preceding time points. In order to compare the individual flux distribu-
tions normalized Hamming distances (see text for formula) have been determined for all pairs
of flux distributions. The darker the color of a matrix entry, the lower is the corresponding
Hamming distance.
to be taken up [435]. Likewise, ATP is imported rather than exported to support the host
as proposed by Kanaani and Ginsburg [237] and hemoglobin is predicted to be taken up
during liver stages where no hemoglobin is present. Furthermore, purine precursors are
imported mostly in the form of inosine, guanosine, and adenosine, while hypoxanthine is
exported, despite being available in higher concentrations in the blood plasma than the
other purine precursors. These discrepancies indicate that further constraints reflecting
the parasites environment are needed in order to obtain more reliable flux predictions. In
addition, uptake of host proteins during other stages than the blood stage and subsequent
degradation of these proteins in the food vacuole seems to be conceivable, as respective
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Figure 6.8: Predicted host parasite metabolite exchanges. Flux distributions have been
predicted with the flux balance approach for each time point of the parasite’s life cycle for which
a gene expression profile exists. Simulations were conducted considering only the metabolic
network of the parasite without any further constraints reflecting the parasite’s environment
and without considering the expression status of genes during preceding time points. Resulting
metabolite exchanges between host and parasite are depicted in this figure. Red matrix entries
represent metabolites that are predicted to be imported into the parasite while green matrix
entries represent metabolites secreted into the host compartment.
peptidases have been detected throughout the developmental cycle.
6.6 Improved metabolic flux predictions for the blood stage
Most of the knowledge about the malaria pathogen P. falciparum is related to the blood
stage, due to simple experimental accessibility and the fact that among the host cells the
erythrocyte is the best studied system. As predictions for the blood stage are assumed
to improve when this knowledge is integrated, the parasite’s metabolic network was com-
bined with that of the erythrocyte, and the combined network was forced to produce in
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addition metabolites important for erythrocyte metabolism. Furthermore, constraints re-
flecting knowledge about the blood stage were incorporated into the calculations. For
example, the parasite was forced to consume at least a certain amount of hemoglobin
and glucose, since both metabolites are known to be consumed by the parasite in large
amounts [133, 251]. Uptake limits were set for several metabolites, including purine precur-
sors, sugars, cofactors and phospholipid headgroup precursors, which are proportional to
the respective blood plasma concentrations as listed in the Human Metabolome Database
(http://www.hmdb.ca/). In addition, constraints were added that ensure trapping of purine
precursors as well as choline and ethanolamine within the parasite due to phosphorylation
[252, 282]. Observations by Mehta et al. [322] indicate that P. falciparum is able to repress
glycolysis of erythrocytes by inhibiting their glycolytic enzymes phosphofructokinase and
pyruvate kinase. In concordance with these observations both host enzymes were inhibited
in flux calculations that correspond to stages subsequent to the ring stage of the IDC.
For a certain fraction of P. falciparum genes, the transcriptome was found to correlate
better with the proteome of the following than the current stage [420]. For this reason, con-
sidering only the gene expression snapshot of a single time point does not give a complete
picture on the actual present proteome. Including the gene expression status of previous
time points into the calculations should therefore further improve flux predictions. The algo-
rithm was modified in such a way that genes were considered to be expressed, if a transcript
is either present during the time point of interest or during a time span of approximately
12 hours prior to this time point (concerns 12 preceding samples of Bozdech data set and
2 preceding samples of Le Roch data set). Since the time intervals between samples cov-
ering the liver or the mosquito stage are larger, this modification was only applied to flux
predictions related to the blood stage.
Metabolites predicted to be exchanged between host and parasite when using the im-
proved algorithm (combination of host and parasite network, additional constraints reflect-
ing knowledge about the blood stage as well as consideration of gene expression status of
preceding time points; see Fig. 6.9 for Hamming distance matrix between calculated flux
distributions) are in considerably better accordance with experimental findings (see Table
6.1 and Fig. 6.10) than before. In contrast to the previous predictions, purine precursors
and choline are only imported and not secreted, while amino acids (except for isoleucine)
are only exported. For the flux calculations hemoglobin is assumed to be digested at higher
rates during trophozoite and schizont stages of the IDC, which releases iron that can be
utilized by the parasite [168, 292, 132]. When the host’s glycolytic enzymes phosphofruc-
tokinase and pyruvate kinase are inhibited (trophozoite and schizont stages), ATP can no
longer be obtained from the host. Thus, the parasite needs to produce more ATP on its
own, which requires the import of additional phosphate. Moreover, in order to ensure host
survival for a certain time period, the parasite provides the host with ATP, which is in
accordance with findings by Kanaani and Ginsburg [237].
In general, flux profiles derived from in vitro (Bozdech and Le Roch data set) and in vivo
gene expression samples (Daily data set) are fairly similar in terms of exchanged metabolites
between host and parasite, especially those corresponding to the active growth like cluster
(cluster 2). One main difference is that more purine precursor types are predicted to be
imported for the in vivo samples. The main differences between in vivo clusters is the
absence of predicted fatty acid and choline import for samples of the starvation like cluster
(cluster 1). This could be attributed to environmental conditions that result in a lack
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Figure 6.9: Normalized Hamming distance matrix for calculated flux distribu-
tions using improved algorithm. Flux distributions have been predicted with the
improved flux balance approach for each gene expression sample derived from the blood stage.
Simulations were conducted on the basis of the combined metabolic network of parasite and
host and additional constraints reflecting knowledge about the blood stage. Furthermore, the
expression status of genes during preceding time points was considered for the flux calculations.
In order to compare the individual flux distributions normalized Hamming distances (see text
for formula) have been determined for all pairs of flux distributions. The darker the color of a
matrix entry, the lower is the corresponding Hamming distance.
of nutrients required for parasite growth. Cell membrane production is then either not
possible or not the main focus and thus the import of membrane precursors like fatty acids
and choline is not required.
There are still some metabolites whose predicted transfer direction through the parasite’s
plasma membrane does not meet literature knowledge. For example, it has been found that
arginine contained in the medium is imported and depleted by the parasite, resulting in
ornithine which is then excreted [366]. In contrast, the simulations suggest arginine export.
Since the experimental observations were made at excessively high arginine concentrations,
further experiments are needed to examine arginine transport under physiological condi-
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Figure 6.10: Predicted host parasite metabolite exchanges using improved algo-
rithm. Flux distributions have been predicted with the improved flux balance approach
(see Fig. 6.6) for each time point of the intraerythrocytic developmental cycle for which a
gene expression profile exists. Simulations were conducted on the basis of the combined meta-
bolic network of parasite and host and additional constraints reflecting knowledge about the
blood stage. Furthermore, the expression status of genes during preceding time points was
considered for the flux calculations. Resulting metabolite exchanges between host and para-
site are depicted in this figure. Red matrix entries represent metabolites that are predicted
to be imported into the parasite, while green matrix entries represent metabolites secreted
into the host compartment.
tions. The predictions are more in line with experiments by Liu et al. [289] which indicate
that hemoglobin degradation satisfies the parasite’s demand for all amino acids during the
blood stage except for isoleucine and thus isoleucine is the only amino acid required to
be taken up. Other predicted metabolite transports that contradict literature knowledge
are those of formate, hydrogencarbonate and ethanolamine. Almost no transport is pre-
dicted for ethanolamine, because the transport process is not associated with any gene and
therefore our algorithm avoids to assign non-zero fluxes. However, this is not the case for
formate and hydrogencarbonate, but rather missing reactions and transport processes in the
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erythrocyte that are needed to dispose of these metabolites. Thus, predictions can still be
further improved when more knowledge is available on the particular developmental stages
as well as the host cell.
Counting for each metabolic reaction and transport process in how many stage-specific
flux distributions it is predicted to be active when using the improved algorithm (see Fig.
6.11), reveals that nearly 350 reactions carry a non-zero flux in all 96 flux profiles that are
derived from gene expression samples extracted during the IDC. In comparison to these
globally active reactions, others that are present during fewer time points can be considered
as more stage-specific.
Figure 6.11: Reaction distribution among stage-specific fluxes. For each reaction of the
parasite’s metabolic network it was counted in how many of the flux distributions calculated
with the improved approach the reaction carries a non-zero flux. The resulting histogram is
shown here. The x-axis gives the number of flux distributions which assign a non-zero flux
to a reaction and the y-axis indicates the number of reactions that are present in a certain
number of flux distributions. In other words, the left most bar of the histogram represents the
number of reactions that exclusively occur in a single flux distribution and are therefore very
stage-specific, while the right most bar represents the number of reactions that are present in
all 96 flux distributions related to the blood stage.
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6.7 Calculated fluxes mapped onto metabolic pathways
In order to explore the predicted flux distributions derived from the improved algorithm on
the level of metabolic pathways, a second mapping was done. This time, instead of counting
expressed genes per KEGG pathway, reactions carrying non-zero fluxes were counted, to
assess whether a pathway is active or not and whether there are changes during the IDC
(see Fig. 6.12, 6.13 and Fig. 6.14). Due to the integration of gene expression states of
preceding time points into the calculations, more enzymes are considered to be present than
are suggested by the corresponding gene expression sample. In general, for consecutive time
points the number of active reactions per pathway does not vary as much as the number of
expressed genes per pathway (compare to Fig. 6.2 and Fig. 6.3). Therefore, fewer metabolic
changes are predicted between the individual time points than are suggested by the gene
expression data. Nevertheless, time dependent activity variation can be observed for certain
pathways. For example, fewer reactions corresponding to folate biosynthesis are predicted
to be active during the ring stage than during subsequent stages. In contrast, for the citric
acid cycle as well as sphingolipid metabolism an increase in active reactions is predicted
during schizont and early ring stage.
Predictions derived from in vivo gene expression samples show mainly similar pathway
activity levels. Samples of the starvation-like cluster (cluster 1) vary from the others only
with respect to lipid metabolism related pathways, which have a higher fraction of active
reactions (especially the fatty acid biosynthesis pathway), and energy metabolism. Less
reactions of the glycolytic pathway are active while more reactions of the citric acid cycle
are active compared to cluster 2. The same holds true for some samples of the stress
response-like cluster (cluster 3).
However, for some pathways the flux distributions vary substantially from the reported
expression profiles. For instance, according to the flux predictions, synthesis of terpenoids
(part of steroid synthesis pathway) takes place during the complete IDC, while gene ex-
pression data suggest this pathway to be only active during ring and trophozoite stages.
This is due to the chosen set of target metabolites required to be produced during the in-
dividual stages (see Table 5.2), which includes isopentenyl diphosphate. This might not be
appropriate for all time points.
6.8 Validation with proteomics and metabolomics data
For further validation the predicted stage-specific flux distributions were compared to avail-
able proteomics data. Five data sets were considered in this process, including three data
sets extracted from P. falciparum during blood and mosquito stages [147, 275, 276], one
data set that covers these stages in the rodent malaria pathogen P. berghei [185] and one
data set obtained from the liver stage of P. yoelii, another rodent malaria pathogen [501].
The individual life cycle stages that were analyzed in these studies are listed in Table 2 and
Table 3. For each observed protein sample the percentage of enzymes that is predicted to
be active in the stage-specific flux distributions was calculated and plotted in Fig. 6.15.
Tendentially, if only few enzymes were detected during a specific stage, like the salivary
gland sporozoite stage in the study by Hall et al. (HallPbSporo), a higher percentage of
these enzymes are recovered by the predictions. Accordance between proteome data sets
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Figure 6.12: Predicted metabolic fluxes consistent with Bozdech gene expression
data mapped onto metabolic pathways. Flux distributions have been pre-
dicted with the improved flux balance approach for each time point of the intraerythrocytic
developmental cycle for which a gene expression profile exists. Simulations were conducted
on the basis of the combined metabolic network of parasite and host and additional con-
straints reflecting knowledge about the blood stage. Furthermore, the expression status of
genes during preceding time points was considered for the flux calculations. In order to ex-
plore the predicted flux distributions on the level of metabolic pathways, the flux profiles were
mapped onto KEGG pathways and active reactions were counted, revealing active pathways
and changes during the IDC. The darker the color of a matrix entry the fewer reactions of
the corresponding pathway are active.
and predicted flux distributions does not only depend on the size of the proteome data set,
though. For example, the gametocytes sample (LasonderPfGametocyte) extracted from
blood cultures correlates better with flux distributions predicted for blood stages than the
smaller sporozoite derived sample (FlorensPfSporo). In general, flux distributions predicted
for mosquito stages show less agreement with proteome samples than flux distributions
predicted for other stages. Nevertheless, flux distributions associated with salivary gland
sporozoites (TarunPyooSpz, TarunPysgSpz) have large overlaps with proteome samples of
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Figure 6.13: Predicted metabolic fluxes consistent with Le Roch gene expression
data mapped onto metabolic pathways. Same as Fig. 6.12, but fluxes were
calculated using Le Roch gene expression data.
the same stage (LasonderPfSgSporo, HallPbSporo, HallPbOocyst). Likewise, proteome
samples extracted during the liver stages show best correlation with corresponding predicted
flux profiles. Concerning the blood stage of the parasite’s life cycle, a higher percentage
of enzymes detected during the trophozoite and schizont stage (LasonderPfTrophoSchz,
FlorensPfTropho) are predicted to be active during the schizont stage when considering
those flux distributions derived from Le Roch gene expression samples. For blood stage
related flux distributions derived from Bozdech gene expression samples the trophozoite
proteome samples correlate slightly better with trophozoite stage related flux distributions.
Regarding the in vivo expression sample derived predictions more agreement with blood
stage proteome is found for samples of cluster 1 and 3.
Additionally, predicted flux distributions were analyzed with respect to metabolites that
are produced or consumed by active reactions and thus should be present during the re-
spective stage. These metabolites were compared to experimentally determined sets of
metabolites detected during seven time points of the intraerythrocytic developmental cycle
(Olszewski data set) [366] or extracted with different methods from mature trophozoites
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Figure 6.14: Predicted metabolic fluxes consistent with Daily gene expression
data mapped onto metabolic pathways. Same as Fig. 6.12, but fluxes were
calculated using Daily gene expression data.
(Teng data set) [503], respectively. The percentage of experimentally detected metabolites
covered by predictions was computed for each of the eleven sets (see Fig. 6.16). Since
the Teng metabolomics samples are quite small and contain mostly metabolites of the core
metabolism, they are almost all present in all life cycle stage-specific flux predictions. In
contrast, less metabolites of the Olszewski samples are recovered by the predictions. Nev-
ertheless, more than 80% of the metabolites contained in these sets (which are more than
double the size of the Teng metabolite sets) are involved in reactions that are predicted to
be active during the blood stage. All seven Olszewski samples consist of the same meta-
bolites (only concentrations vary during the individual time points), suggesting that these
metabolites are present during the whole IDC. Discrepancies between predictions and ex-
perimental results are not necessarily due to limited prediction quality. For example, it is
conceivable that metabolites diffuse into the cell and are experimentally detected, but no
enzyme is expressed that is able to convert the metabolite. Furthermore, the metabolomics
samples contain less than one hundred metabolites, suggesting that a large fraction of the
actually present metabolites were not experimentally analyzed.
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Cluster 1 Cluster 2 Cluster 3
Figure 6.15: Overlap of experimentally determined proteins with stage-specific
sets of enzymes predicted to be active. The applied proteome samples (y-axis)
are specified in Table 2. Numbers in parenthesis indicate the number of genes that correspond
to the metabolic network and are covered by a proteomics sample (y-axis) or the number
of genes associated with active reactions (x-axis), respectively. Matrix entries depict the
percentage of experimentally determined metabolic enzymes recovered by the stage-specific
flux predictions. Improved predictions were considered for blood stage flux distributions.
6.9 Determination of fluxes with higher reliability
For each stage of the parasite’s developmental cycle, so-called consensus reactions were
determined that are predicted to be active for all gene expression samples covering the
same stage. These reactions are more likely to actually occur during a certain stage, since
they are derived from different data samples. In order to identify consensus reactions, all
calculated flux profiles were grouped into 13 sets (LS24, LS40, LS50, eRing, lRing, eTropho,
lTropho, eSchiz, lSchiz, Mero, Gameto, ooSporo, sgSporo; see Table 1) with respect to
represented stages, and those reactions were determined that carry a non-zero flux in all
flux profiles of the same set. For all stages of the intraerythrocytic developmental cycle
those flux profiles were considered that were calculated with the improved algorithm.
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Cluster 1 Cluster 2 Cluster 3
Figure 6.16: Overlap of experimentally determined metabolites with stage-
specific sets of metabolites predicted to be present. The applied
metabolomics samples (y-axis) are specified in Table 3. Numbers in parenthesis indicate
the number of metabolites that correspond to the metabolic network and are covered by
a metabolomics sample (y-axis) or the number of metabolites involved in a predicted flux
distribution (x-axis), respectively. Matrix entries depict the percentage of experimentally de-
termined metabolites recovered by the stage-specific flux predictions. Improved predictions
were considered for blood stage flux distributions.
For each blood stage and each metabolic pathway the fraction of consensus reactions per
total number of pathway reactions was computed to uncover the distribution of consensus
reactions among pathways (see Fig. 6.17). To get an impression of how many consensus
reactions are shared between the different stages, this fraction was also computed for those
consensus reactions that two sets have in common. In several pathways the same reactions
are active during the whole IDC (e. g. ubiquinone biosynthesis and terpenoid biosynthesis).
These are mostly biosynthesis pathways where alternative routes are rare and the endprod-
ucts are considered to be essential. Therefore, the network is forced to produce them, which
results in a large overlap between the predicted fluxes through these pathways for all time
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Figure 6.17: Overview of pathway specific consensus reactions for different time
points of intraerythrocytic cycle. Consensus reactions (reactions that are pre-
dicted to be active for all gene expression samples, covering the same stage) were determined
for all stages of the IDC. These reactions are more likely to actually occur during a certain
stage, since they are derived from different data samples. In order to identify consensus re-
actions, all calculated flux profiles corresponding to the blood stage were grouped into seven
sets (see Table 1) with respect to represented stages and those reactions were determined
that carry a non-zero flux in all flux profiles of the same set. For each blood stage and each
metabolic pathway the fraction of consensus reactions per total number of pathway reactions
was computed to uncover the distribution of consensus reactions among pathways. To get
an impression of how many consensus reactions are shared between the different stages, this
fraction was also computed for those consensus reactions that two sets have in common. The
darker the color of a matrix entry the lower is the percentage of consensus reactions.
points. By contrast there are pathways where more accordance can be observed for tropho-
zoite and schizont stages (e.g. glutathione metabolism, pentose phosphate pathway). This
is mainly due to the fact that consensus reactions for the early and late ring stage are de-
rived from many more samples than those for other stages. Especially the heterogeneous in
vivo expression samples contribute to a low number of consensus reactions for these stages.
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The citric acid cycle is one of the few pathways where a certain level of agreement exists
between ring and schizont stages.
6.10 Discussion
A relatively simple approach to obtain global insight into the metabolism of a cell under
certain conditions is to analyze gene expression and to infer active metabolic pathways
based on the presence of corresponding enzyme mRNA transcripts (e.g. [56, 567, 234, 437]).
Multiple tools have been developed in the last years to aid this process [93, 374, 334, 286].
However, more detailed information such as flux rates and flux directions cannot be gained
from gene expression data alone. Additional metabolomics and tracer experiments are
required to obtain this information. A computer based alternative is flux balance analysis,
which derives metabolic flux rates by solving an optimization problem that reflects the flux
balance principle and an assumed objective for the metabolism of an organism of interest.
In contrast to kinetic modeling, no detailed rate equations are required, thus making this
method appropriate for large-scale metabolic networks lacking full kinetic characterization.
In this work an approach that combines gene expression data with flux balance analysis has
been applied to P. falciparum to infer life cycle stage-specific metabolism. This strategy
was assumed to complement the weaknesses of each approach, allowing to predict metabolic
fluxes even for those parts of the metabolic network which are not associated with gene
expression data or which might not be covered by the applied objective function due to
incomplete knowledge of cellular objectives. As has been shown, flux distributions derived
from this approach differ for certain pathways from what is expected when only taking
into account gene expression profiles mapped onto metabolic pathways. For example, the
terpenoid biosynthesis pathway is predicted to be active during the whole IDC, while few
genes of this pathway are expressed during merozoite and ring stage. These discrepancies are
due to the chosen target metabolites whose production requires enzymes of this pathway to
be active. To evaluate whether these predictions are inadequate or mRNA levels are simply
not fully conclusive, experimental data of present enzymes and pathway intermediates are
needed. Comparisons with experimentally observed enzyme and metabolite profiles revealed
good accordance for most of the stage-specific flux distributions. However, due to the small
number of examined stages as well as the relatively small number of measured enzymes and
metabolites, detailed evaluation of predicted flux distributions is not possible. Differences in
predicted fluxes and observed enzyme profiles might additionally be caused by the applied
signal-to-noise cutoff for the classification of gene expression. Especially for the Tarun data
set, where a high cutoff was chosen and thus more genes are considered to be not expressed,
this could play a role. Another issue could be the fact that only one solution was considered
here, but FBA might yield multiple solutions, which are equally optimal with respect to
the applied objective function. It is possible that alternative optimal solutions agree better
with experimental data. Therefore, prediction improvements could be obtained when flux
ranges are considered that reflect alternative solutions rather than fixed flux values. Such
ranges can be determined with the help of a concept called flux variability analysis [300].
Integration of available information about present enzymes and metabolites will further
improve FBA predictions.
In general, better predictions could be obtained if more details were known about the
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biochemical composition of the parasite during the different developmental stages, allowing
to use for each stage an adapted set of target metabolites. Furthermore, incorporation of
additional information such as available nutrients, capacities of transport proteins and host
cell metabolism would further improve predictions as has been demonstrated for stages of
the intraerythrocytic developmental cycle. Until such information is available for all stages
of parasite development, flux distributions derived from flux balance analysis and gene
expression data are a good starting point to get an insight on the parasite’s metabolism on
genome-scale.
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Identification of putative drug targets
7.1 Introduction
Typically, the first step in the drug discovery process is the identification and validation
of a suitable drug target. Subsequently, a potential drug is determined by either high-
throughput screening against a library of drug-like compounds or rational drug design. In
order to prevent waste of resources, it is important that the target candidate is well chosen.
Several criteria exists that help to identify potent drug targets. The two most important
properties are: (1) the target is druggable, i.e., the target possesses a binding site for
small molecules that might modulate its activity and (2) the target is essential for disease
progression.
Druggable proteins have been analyzed with respect to common structural features, re-
vealing that these characteristics are good predictors for potential targets [575, 353, 89].
In case structural information is not available, genomic sequence properties shared among
drug targets have been shown to be an alternative basis for druggability predictions [25].
Proteins critical for processes involved in disease progression can be detected by net-
work based approaches that consider the whole system and not only local properties. If
a pathway has been found to be essential for disease progression and kinetic information
is available for all involved enzymes, metabolic control analysis can be used to determine
those enzymes that have the largest influence on the pathway and thus presumably repre-
sent efficient targets [76, 211]. However, very often such information is not available. A
relative simple alternative method is the choke-point analysis, which identifies reactions
that are for particular metabolites the only source or sink in the metabolic network of
interest [561, 188, 472, 473]. Inhibition of such reactions results in accumulation or deple-
tion of these metabolites with presumably negative effects on the cellular system. Many
known drug targets in the metabolism of pathogens have been shown to be choke-points
[561, 472]. A major disadvantage of this method is the high number of predicted targets.
Other proposed network based drug target detection approaches have in common that a
certain knowledge about the cellular objective is required, e.g., target metabolites essential
for the development of pathogenic cells. An example hereof is a concept called minimal cut
sets, which determines a minimal set of blocked reactions that are required for the inacti-
vation of certain network functions [256, 255, 189]. Computation time for large metabolic
networks is quite high, though, as the approach requires to compute all feasible and bal-
anced flux distributions for the network of interest (elementary flux modes) whose number
grows exponentially with network size. An approach that is characterized by relatively
low computation times is flux balance analysis. This concept has been applied to simulate
knockouts in several organisms with good agreement between phenotype predictions and
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experimental observations [135, 279, 233, 377, 131].
7.2 Detection of essential reactions via flux balance analysis
The main goal of this work is the identification of novel putative drug targets in Plasmodium
falciparum. For this purpose flux balance simulations were conducted, in order to analyze the
compiled metabolic network with regard to essential reactions required for the production
of important cellular metabolites. Enzymes catalyzing such reactions represent potential
drug targets, since their inhibition would result in a shortage of required metabolites and
thereby in impaired development. The linear program underlying the knockout simulations
conducted in this study reads as follows:
min
v
∑
| vi | (7.1)
s. t.: Sv = 0 (7.2)
vmin,i < vi < vmax,i (7.3)
vi > 1 for target metabolite efflux (7.4)
vi = 0 for knocked-out enzymes (7.5)
Here, S is the stoichiometric matrix of the cellular system, vi are internal fluxes as well as
exchange fluxes, and vmin and vmax represent lower and upper bounds on fluxes. The solu-
tion space that contains all feasible flux distributions is defined by linear equations derived
from the steady-state assumption (7.2) as well as thermodynamics and knowledge about
enzyme and transporter capacities (7.3). Production of metabolites assumed to be essen-
tial during any time point of parasite development (see Table 5.2) is ensured by forcing an
efflux of these metabolites through the system boundary (7.4). In addition, fluxes through
a reaction of interest are fixed to zero, mimicking the knockout of the corresponding gene.
For each reaction of the metabolic network of P. falciparum such a linear program was
formulated. In case the solution space of the problem was empty, the knocked-out reaction
was considered to be indispensable. Hence, the corresponding enzyme represents a putative
drug target, since no path exists converting external nutrients into all target metabolites,
which presumably results in impaired parsite development. In contrast to the FBA cal-
culations conducted in the previous chapter, no gene expression data was considered for
the identification of essential reactions. Furthermore, no assumptions were made about the
cellular environment and nutrient uptake was not restricted.
As not all metabolites are equally important during all time points of parasite develop-
ment, e.g., DNA building blocks are not required to be synthesized during the merozoite
stage, a reaction detected by this means might not be globally essential, but rather during
those time points when the particular metabolite requiring the activity of the reaction is
indispensable. On the other hand, certain reactions that are not detected as essential might
be incorrectly classified if nutrients are in reality not available in sufficient amounts during
all time points, which is in contradiction to the simulation assumption. In this case essential
metabolites cannot be derived from imported precursors, but rather need to be completely
synthesized, making additional reactions indispensable. To sum up, all reactions identified
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as essential by this approach are essential during at least one developmental stage, but not
all reactions that are essential during any stage are necessarily recovered.
7.3 Essential reactions in the metabolism of P. falciparum
Flux balance knockout simulations identified 307 reactions that are essential for the para-
site. To evaluate these results a gold standard set was compiled containing 57 enzymes that
were shown to have antimalarial effects upon inhibition or silencing (see Table 7.1). 35 of
these gold standard enzymes correspond to reactions that were predicted to be indispens-
able. Blocking simultaneously all reactions catalyzed by the same gene product recovered
two further targets (dihydrofolate reductase and hypoxanthine phosphoribosyltransferase)
contained in the gold standard set. Among the 20 remaining enzymes 13 were detected as
essential, if additionally transporters were constrained that import biomass precursors by-
passing the respective enzyme. For example, inhibition of the spermidine transporter makes
the spermidine synthase indispensable. These enzymes are therefore either not metabolically
essential during all environmental conditions, but only during those stages where particular
nutrients are not present in sufficient amounts, or the respective parasitic transporters are
not efficient enough. Furthermore, GMP synthase was detected if the import of guanine
and guanosine was constrained and all reactions catalyzed by the enzyme were blocked.
Ornithine decarboxylase was not found by this means, as a an alternative path exists to
synthesize putrescine, which involves carbamoylputrescine amidase. Blocking this enzyme
in addition to the spermidine and putrescine transporters makes ornithine decarboxylase in-
dispensable. Carbamoylputrescine amidase is very likely not present in P. falciparum, since
it was added in the BioCyc database to fill gaps in the putrescine biosynthesis pathway of
which only one enzyme is associated with a gene. Succinate dehydrogenase and NADH dehy-
drogenase, which are not even detected when nutrient import is limited, are presumably false
positives. For both enzymes of the mitochondrial electron transport chain antimalarial ac-
tivity was demonstrated through inhibition with substrate analogs of ubiquinone [267, 492].
As ubiquinone, the substrate of both enzymes, can be provided with electrons by several
enzymes (succinate dehydrogenase, NADH dehydrogenase, dihydroorotate dehydrogenase,
FAD-dependent glycerol-3-phosphate dehydrogenase, malate-quinone oxidoreductase), it is
not quite obvious why inhibition of only one enzyme should result in impaired parasite
development. One explanation could be that the ubiquinone analogs do not only inhibit
one enzyme, but also others that use ubiquinone as a substrate. This is supported by the
findings of Painter et al. [371] who discovered that an active mitochondrial electron trans-
port chain might only be required for the disposal of electrons derived from dihydroorotate
dehydrogenase, an essential enzyme for pyrimidine biosynthesis. They showed that par-
asites expressing the corresponding yeast enzyme, which does not require ubiquinone as
an electron acceptor, are insensitive to atovaquone, an inhibitor of the electron transport
chain Complex III. This suggests that the antimalarial effect of ubiquinone analogs was
rather due to either additional inhibition of the downstream Complex III or simultane-
ous inhibition of all enzymes providing ubiquinone with electrons (including dihydroorotate
dehydrogenase), instead of the sole inhibition of succinate dehydrogenase or NADH de-
hydrogenase. The simulations indicate furthermore that neither sole inhibition of choline
kinase nor sole inhibition of phosphoethanolamine methyltransferase kills the parasite, be-
72
Chapter 7 Identification of putative drug targets
cause phosphatidylcholine can be derived from choline as well as from ethanolamine [385].
The question remains whether these pathways are indeed able to fully compensate the loss
of the alternative pathway, as both have been suggested to affect parasite growth [92, 553].
However, the findings by Choubey et al. [92] can also be explained by unspecific inhibitor
binding (both experiments utilized miltefosin analogs), resulting in the inhibition of both
choline kinase and phosphoethanolamine methyltransferase [385]. Finally, the gold standard
enzyme fructose-bisphosphate aldolase was not detected by the knockout simulations. Es-
sentiality of this glycolytic enzyme was not confirmed by the simulations, since ATP can be
generated from glycerol-3-phosphate (derived from imported glycerol) and glyceraldehyde-
3-phosphate (produced in pentose phosphate pathway), which enter glycolysis downstream
of the enzyme. These metabolites might yield lower amounts of ATP, though, due to the
lower concentration of glycerol in the blood compared to glucose. Buscaglia et al. [68]
demonstrated that aldolase bridges the actin-myosin motor, which is involved in gliding
motility and host cell invasion, and an invasin protein that connects to host cell receptors.
Metabolite (and drug) binding to aldolase prevents interactions between aldolase and the
invasin protein, which has negative effects on parasite motility. Therefore, the observed
reduction of parasitemia upon aldolase inhibition might rather be caused by impaired host
cell invasion than metabolic effects.
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7.4 Performance comparison with choke-point analysis
Previously, two methods have been presented to predict drug targets in P. falciparum
[561, 136]. Both approaches apply the concept of choke-points, which are reactions that
are the only source or sink for at least one metabolite. To compare the performance of
the FBA method and that of choke-point analysis, all choke-points were identified in the
compiled metabolic network and assessed with the gold standard set of drug targets (see
Table 7.1). 679 choke-point reactions were detected in the network, including reactions
that are catalyzed by 37 enzymes of the gold standard. Thus, choke-point analysis recovers
more true targets than the above described flux balance approach. However, due to the
large number of reactions predicted as essential by the choke-point analysis, the flux bal-
ance approach results in higher values for specificity, accuracy and precision and therefore
a better enrichment of true targets (see Fig. 7.1). This means that a choke-point analysis
might end up detecting more true targets, but the flux balance approach will result in a set
of predicted targets with a lower percentage of false positives, which reduces the waste of
experimental resources needed to validate the predictions.
Gold Standard
Pr
ed
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n
Target No target
N
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l
Sum
Sum
TP
FN
FP
TN
35
37
272
642
307
679
22
20
1046
676
1068
696
57 1318 1375
Sensitivity =                        =
TP
TP+FN
Specificity =                        =
TN
TN+FP
Accuracy   =                        =
TP+TN
all
Precision   =                        =
TP
TP+FP
61.4%
64.9%
79.4%
51.3%
78.6%
51.9%
11.4%
5.5%
Enrichment
factor
Precision
all
2.75
1.3
=                        =
TP+FN
Figure 7.1: Evaluation of predicted drug targets. FBA based knockout simulations were
conducted to uncover reactions within the parasite’s metabolic network that are essential for
the production of development relevant metabolites (see Table 5.2). The predicted set of indis-
pensable reactions, which presumably represent good drug targets, was evaluated on the basis
of a gold standard set that contains 57 experimentally verified essential enzymes. True posi-
tives (TP), false positives (FP), false negatives (FN), and true negatives (TN) were determined
in order to calculate based on these numbers sensitivity, specificity, accuracy and precision of
the method as well as the corresponding enrichment factor (red numbers). To compare the
performance of the FBA method to the previously proposed choke-point analysis, additionally
all choke-points within the parasite’s metabolic network were identified and the same statistics
were calculated (green numbers).
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7.5 Ranking of predicted drug targets
Some of the targets predicted by the flux balance approach that are not covered by the gold
standard might nevertheless be valid targets. To address this question, the SuperTarget
database [179] was queried with the respective EC numbers to check whether some of these
reactions are catalyzed by enzymes that were previously targeted in the course of medical
treatments or were shown to have effects on the viability of an organism or pathogenic cell.
Of 155 reactions that are assigned to genes and are predicted to be essential but are not
covered by the gold standard enzymes, 39 correspond to enzymes that are listed in the
SuperTarget database as drug targets.
To avoid unwanted side effects within the human host, it is beneficial to target para-
sitic enzymes that are not homologous to human enzymes. Therefore a BLAST search was
completed on human protein sequences (non-redundant protein sequences) using the pre-
dicted parasitic protein sequences from PlasmoDB as queries. Analogous to [561] an E-value
significance threshold of < 0.075 was applied to determine homologous sequences. Of the
198 reactions that were predicted to be essential and are associated with genes, 168 are
catalyzed by enzymes that are homologous to human enzymes. The gene products catalyz-
ing the remaining 30 reactions represent presumably good drug target candidates. Targets
with human homologs may still be interesting targets as long as binding sites for potential
inhibitors are sufficiently distinct.
As discussed above, reactions predicted to be essential are not necessarily essential during
all time points. Therefore, the stage-specific metabolic fluxes calculated in the previous
chapter were considered to get an idea during which stages reactions are essential. In this
context, the consensus reactions calculated for each life cycle stage (reactions that carry a
non-zero flux in all flux profiles corresponding to the same life cycle stage) were mapped
onto the set of essential reactions (see Table 4). This mapping gives a hint on targets that
are present during all time points as opposed to those that are only active during certain
stages. Depending on the time point when a reaction of the latter type is essential, drugs
designed to inhibit the respective enzyme can either be applied as prophylactic drugs to
kill the liver stages of the parasite and prevent disease symptoms or to treat the disease by
killing blood stages of the parasite, respectively.
Predicted drug target reactions that do not correspond to the gold standard set, but are
associated with genes, were ranked according to a score that represents the sum of weighting
factors assigned to the following features (see Table 4): weighting factor 2 if corresponding
genes are not homologous to human genes, weighting factor 1 if the enzymatic function is tar-
geted in any organism (i.e., EC number is listed in the SuperTarget database) and weighting
factor 1 if the reaction is active during all parasitic life cycle stages. The latter weighting fac-
tor prioritizes exemplarily those targets that are suitable for prophylaxis and disease treat-
ment. Depending on which developmental stage of the parasite one is interested in to inhibit
this weighting factor can be adapted. The 30 top ranking targets are listed in Table 7.2.
Strikingly, among the eight top ranking enzymes/transporters four enzymes and one trans-
porter are assigned to the apicoplast, which harbors prokaryotic biochemical pathways and
was therefore proposed as an interesting drug target [403, 546]. Three of the top ranking en-
zymes are involved in the biosynthesis of isopentenyl diphosphate (IPP). Since two enzymes
of the IPP biosynthesis pathway (1-deoxy-D-xylulose-5-phosphate reductoisomerase, 2-C-
methyl-D-erythritol-2,4-cyclodiphosphate-synthase) have already been suggested as poten-
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tial targets for antimalarial therapy [230, 77, 109], it is likely that other enzymes of this linear
pathway have also this potency. P. falciparum possesses a pathway to synthesize pyrimidine
nucleotides de novo. Multiple reactions of this pathway are predicted to be essential and
for some of them (carbonic anhydrase, carbamoyl-phosphate synthase, dihydroorotase, dihy-
droorotate oxidase, orotidine-5’-phosphate decarboxylase) inhibition has already been shown
to have negative effects on growth [411, 148, 451, 454, 268, 318, 27, 52, 194, 455, 41, 327],
suggesting that the parasite cannot fully compensate the loss of pyrimidine biosynthesis
by import. Thus, other enzymes that catalyze intermediate reactions might be likewise
essential as proposed by the predictions. The heme (porphyrin) biosynthesis pathway has
previously been proposed as a target for antimalarial drugs [493, 55, 520], as heme is needed
as a prosthetic group in proteins such as cytochromes. Heme, which is freed in large amounts
during hemoglobin digestion, is presumably unavailable to the parasite outside of the food
vacuole [493, 517], making de novo synthesis essential. This is in accordance with the pre-
dictions that classified several enzymes involved in heme biosynthesis to be indispensable.
Another pathway that contains reactions predicted to be essential is that of Coenzyme A
(CoA) biosynthesis. It has been demonstrated that the parasite relies on the uptake of
pantothenate, a precursor of CoA, and that it is sensitive to pantothenate analogs [482].
Therefore, inhibition of downstream enzymes within this linear pathway might hamper par-
asite growth as well. Multiple top ranking enzymes are involved in the process of protein
biosynthesis (tRNA ligases, deoxyhypusine synthase). The eukaryotic translation initiation
factor eiF5A, whose activation involves deoxyhypusine synthase, has already been suggested
to be the target of a drug with antimalarial effect [236]. Despite the obvious global effect
upon inhibition of the translational machinery, relatively few is known about this process
in P. falciparum. Therefore, an EU funded consortium called MEPHITIS has started very
recently to explore the protein synthesis machinery in Plasmodium with the goal to design
drugs against malaria. Adenylate cyclase obtained among others the highest score by the
scoring function. Experimental findings by Ono et al. [367] indicate that knockouts of
adenylate cyclase result in a decreased level of cAMP, leading to reduced apical regulated
exocytosis and thus impaired infection of host cells. The essentiality of this enzyme is there-
fore related rather to signaling than to metabolism, but nevertheless represents an effective
target. These evidences for the plausibility of the results together with the proven high
specificity and accuracy rates for known targets indicate that the predicted set of essential
reactions presents a promising starting point for further experimental investigations.
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7.6 Discussion
Experimental validation of drug targets with the help of gene knockout techniques is a time
consuming issue. Flux balance analysis provides a fast means to reduce the search space,
since reactions essential for parasite development can be identified on the basis of their
involvement in the synthesis process of indispensable metabolites. Drug targets predicted
in this work were evaluated on the basis of a set of known essential enzymes, revealing
that the applied flux balance approach is able to enrich true targets in the set of predicted
targets. The presented FBA approach has the advantage over other computational drug
target detection methods that it performs reasonably well, as has been demonstrated by a
comparison with choke-point analysis, and that it requires only short computation times.
The latter plays a role especially when the metabolic network of interest is large and beyond
the capabilities of methods such as minimal cut sets that need to explore all paths through
a network.
Additional information including homology to host enzymes and reported negative effects
on cell development in other organisms was used to rank proposed targets. Targets with
high ranks were found to be involved in metabolic pathways, which contain enzymes already
known to be essential for parasite development.
As has been shown for fatty acid synthase [526], which is only essential during late liver
stage, the importance of enzymes might vary during different life cycle stages. Therefore,
predictions of metabolic fluxes during the individual stages of parasite development may
help to identify reactions that are always active opposed to those that only occur during
certain stages. By this means, targets can be identified that are suitable for prophylaxis,
therapy or both (depending on the applied scoring criterion), thereby aiding the drug target
detection process.
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Conclusions and outlook
The goal of this work was to explore the capabilities of systems biology methods in the con-
text of drug target detection within the metabolism of the malaria pathogen P. falciparum
and distinction between targets suitable for malaria prophylaxis, therapy or both. For this
purpose, a comprehensive multi-compartment metabolic network was compiled for the par-
asite based on data from several resources. This network was validated by flux balance
simulations to obtain a consistent network that is able to fulfill metabolic processes, such as
hemoglobin digestion, known from the literature to occur in P. falciparum. With the help of
an adapted version of the method proposed by Shlomi et al. [465], metabolic flux distribu-
tions corresponding to the parasite’s individual life cycle stages were derived from gene ex-
pression profiles measured during respective stages. These predicted flux distributions were
shown to agree well with literature knowledge in terms of exchanged metabolites between
parasite and host during the blood stage. However, it was necessary to integrate additional
information into the calculations in order to obtain this level of accordance. The meta-
bolic network of the parasite was combined with that of the erythrocyte and stage-specific
knowledge like plasma metabolite concentrations was considered to account for the actual
cellular environment of the parasite. In addition, gene expression data of previous stages
were included, since enzymes might be present although corresponding gene transcripts are
already degraded. Experimentally determined exchanges between host and parasite are
only available for the blood stage, preventing evaluation of predictions corresponding to
other stages. As predictions depend on the incorporation of further information, predic-
tion quality is likely to be limited for those stages where it was not possible to integrate
such information (liver and mosquito stages). This is also suggested by proteomics data,
which coincide better with blood stage flux distributions than with those corresponding to
mosquito stages. Considering available proteomics and metabolomics data, will presumably
improve predictions, as such data are closer to the phenotype than gene expression data due
to posttranscriptional regulation. Flux predictions for liver stages can be further improved
when the metabolic network of the hepatocyte, which has been completed very recently, is
integrated into the calculations.
The assembled metabolic network of P. falciparum has been shown to be useful with
respect to identification of putative drug targets. About two thirds of experimentally vali-
dated essential enzymes could be recovered by flux balance knockout simulations. Almost all
remaining true targets were detected when additionally available nutrients were constrained,
suggesting that the parasite is not able to compensate inhibited pathways by import of re-
spective nutrients although transporters exist. More information about provided nutrients
as well as target metabolites is required to improve predictions, as enzyme essentiality does
not only depend on network topology, but also on the cellular environment present during
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a stage of interest. This is supported by the results of a comparison between choke-point
analysis, a pure topology based method, and the here applied flux balance approach, which
succeeds the former in terms of specificity, accuracy and precision.
For the knockout simulations a set of target metabolites was considered that includes all
metabolites essential during any life cycle stage of the parasite. Therefore, not all enzymes
that were found to be indispensable are essential during all stages. Overlaying the metabolic
network with stage-specific flux predictions, reveals which enzymes come into question as
targets during the different stages, i.e., which targets are suitable for malaria prophylaxis
(essential during liver stages) or malaria treatment (essential during blood stages).
With regard to the iterative cycle underlying systems biology approaches (see Fig. 1.2),
the present work is currently in the phase of hypothesis generation. A model describing the
metabolism of P. falciparum has been constructed based on available data and simulations
have been conducted that allow to make predictions on stage-specific metabolism and on
effects of knockouts. These predictions now await experimental validation. Data derived
from these experiments will then help to refine the model and to improve predictions until
the model reproduces reality reasonably well.
The current trend is to refine predictions by combining reconstructed cellular networks
with different types of high-throughput data, e.g., metabolic networks with gene expression
data as presented here. Since proteomics data and to a smaller extent metabolomics data
are available for P. falciparum, future extensions of the parasite’s metabolism model could
include constraints reflecting these data. In addition, observed protein-protein interactions
could be used to distinguish isoenzymes from components of a multi-enzyme complex, which
only fulfill their function when all components are expressed simultaneously. P. falciparum
genes are assumed to be posttranscriptionally regulated, but increasing hints suggest that
regulation at the level of transcription initiation also plays a role [59, 271, 290, 291]. Tran-
scription factors have been identified by bioinformatics approaches [161, 72] and putative
cis-regulatory elements have been detected by statistical analysis of promoter regions of
co-expressed genes [564]. In addition, ChIP-on-chip (chromatin immunoprecipitation) tech-
nology is available that will help to investigate interactions between proteins and DNA, thus
identifying transcription factors and respective promoter regions. These efforts will even-
tually allow to reconstruct the gene regulatory network of the parasite, which can then be
combined with the metabolic network. By this means, the impact on metabolism and hence
parasite viability upon inhibition of transcription factors can be assessed and putative drug
targets identified. The more experimentally determined information can be incorporated
into the model, the less assumptions have to be made. The ultimate goal is a compre-
hensive model that combines metabolism, gene regulation and signal transduction, making
assumptions about cellular objectives redundant, as they are intrinsic to the model itself.
85
Applied experimental data
1 Gene expression data
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